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Sepsis still rem
ains the leading cause of adm
issions and deaths 
in the IC
U
. The adm
inistration of antibiotics is im
perative in its 
treatm
ent. Like m
any areas of m
edicine the know
ledge of sepsis 
and antibiotic use has m
arkedly increased especially the latter in 
areas of pharm
acokinetics and pharm
acodynam
ics. It becom
es 
urgent to continually evaluate and apply this know
ledge, hence the 
need to revise this antim
icrobial guide after five years.
The threat that one day antibiotics m
ay be obsolete is not a 
fallacy. O
ften w
e are oblivious to the fact that w
e, the prescribers, 
play a significant role in the propagation of resistant organism
s 
through poor prescribing habits. A
ntibiotic stew
ardship calls for a 
m
ultidisciplinary approach to the handling of antibiotics. A
 chapter 
has been dedicated to this.
The book rem
ains true to its aim
s as a convenient up-to-date pocket 
guide for local doctors caring for the critically ill septic patient. 
H
ow
ever it m
ust be em
phasised that the recom
m
endations do not 
over ride sound clinical judgem
ent and local antibiotic-susceptibility 
data.
W
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ould like to thank our review
ers for their expertise and 
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endations. This book has been a culm
ination of 
m
any hours of evidence review
 and exchange of opinions. W
e hope 
it w
ill be a useful com
pendium
 for daily practice.
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A
 new
 chapter on antibiotic stew
ardship.
In 
line 
w
ith 
m
ore 
evidence 
and 
better 
understanding 
of 
pharm
acokinetics and pharm
acodynam
ics of antibiotics, som
e new
 
dosing has been introduced:
	
•	Loading	
doses	
recom
m
ended	
for	
certain	
antibiotics	
e.g.	
 
 
fluconazole, ceftriaxone.
	
•	Polym
yxin	and	high-dose	sulbactam
	dosing	has	changed.
	
•	Expanded	appendix	on	dose	adjustm
ent	for	renal	failure.
	
•	A
ppendix	on	drugs	affected	by	hypoalbum
inaem
ia.
	
•	A
ppendix	on	drug	dosing	in	obesity.
The use of cefoperazone/sulbactam
 to deliver high dose sulbactam
 
has 
been 
om
itted, 
as 
it 
w
ould 
exceed 
daily 
dose 
lim
its 
of 
cefoperazone. C
efoperazone increases the risk of coagulopathy.
O
ther new
 recom
m
ended dosing:
	
•	IV	cefepim
e	2g	q8h
	
•	IV	ceftriaxone	1g	q12h	
	
•	IV	ceftazidim
e	2g	q6h	in	m
elioidosis	
	
•	IV	cloxacillin	2g	q4h
	
•	IV	gentam
icin	3m
g/kg	q24h	in	endocarditis
	
•	IV	im
ipenem
	1g	q8h	for	severe	infections
Potential	use	of	inhaled	polym
yxin	and	am
ikacin	as	adjunct	to	IV	
therapy in the treatm
ent of ventilator-associated pneum
onia caused 
by certain m
ulti-drug resistant organism
s.
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1The dilemma of current antibiotic use in ICUs is the balance between providing adequate coverage against likely 
pathogens and at the same time minimising selection of antibiotic resistant organisms. Antibiotic stewardship 
refers to activities that help optimise antibiotic therapy, ensuring the best clinical outcome for the patient while 
lowering the risk of development of antimicrobial resistance and minimising adverse effects and costs.
Appropriate measures in antibiotic stewardship in ICUs include:
1. Rapid identification of patients with infections
	 •	 An	accurate	diagnosis	of	bacterial	infection	should	be	made	before	administration	of	any	antibiotics.
	 •	 Obtaining	 specimens	 for	 appropriate	 cultures	 before	 antibiotic	 administration	 is	 essential	 to	 confirm
  infection, identify responsible pathogens and enable de-escalation therapy. However, the results are often
	 	 unavailable	for	the	first	24	hours.
	 •	 The	decision	to	start	antibiotics	in	a	possibly	infected	critically	ill	patient	needs	to	be	balanced	between
	 	 the	uncertainty	of	infection	and	risk	of	delaying	treatment	against	the	overuse	of	antibiotics.	Observational
  data suggested that delaying antibiotics in haemodynamically stable surgical patients with suspected
  intensive care unit- acquired infections could be an option when exercised with sound clinical judgement. 
	 •	 Currently,	there	is	no	biomarker	of	infection	that	clinicians	can	rely	exclusively	on.
	 •	 Molecular	diagnostic	testing	has	the	potential	to	be	used	for	timely	and	rapid	identification	of	causative
  micro-organism.
ANTIBIOTIC STEWARDSHIP IN ICU
22. Ensure appropriate empiric antibiotic therapy
	 •	 Appropriate	 therapy	 is	 defined	 as	 the	 use	 of	 antibiotics	 at	 its	 correct	 dose,	 in	which	 the	 organism	 is
  susceptible to, as determined by in vitro tests. 
	 •	 Studies	have	shown	that	early	use	of	appropriate	antibiotic	therapy	improves	outcome.
	 •	 Empirical	therapy	should	be	based	on	regularly	updated	local	data	on	the	incidence	of	causative	organisms
  and their susceptibility to antimicrobial agents. This applies to both community and hospital-acquired
  infections.
	 •	 Another	 consideration	 in	 selection	 of	 antibiotics	 includes	 previous	 antibiotic	 use	within	 the	 preceding
	 	 2	weeks.	Whenever	possible,	do	not	use	the	same	class	of	antibiotics.
3. Minimise time to initial antibiotic dose
	 •	 The	timing	of	initial	therapy	should	be	guided	by	the	urgency	of	the	situation.	
	 •	 In	critically	ill	patients	with	septic	shock,	patients	with	febrile	neutropenia	or	bacterial	meningitis,	empiric
  therapy should be initiated immediately after obtaining microbiological specimens or even before, if the
  procedure is delayed. 
	 •	 In	more	stable	patients,	antimicrobial	therapy	can	be	withheld	until	appropriate	specimens	or	investigations
  have been obtained. 
4. Optimise antibiotic dose and interval
 Factors affecting dosing in the critically ill include:
	 •	 Increase	in	volume	of	distribution	(Vd) of hydrophilic antibiotics
	 	 Vd	 of	 hydrophilic	 antibiotics	 (e.g.	 aminoglycosides,	 beta-lactams,	 vancomycin,	 linezolid,	 polymyxins)	 is
3	 	 increased	in	patients	with	sepsis	and	burns.	These	increases	in	Vd can cause lower than expected plasma
	 	 concentrations	during	the	first	day	of	therapy.	Larger	Vd will require the administration of loading doses
  to saturate body tissues where the drug distributes to whilst still achieving appropriate concentrations at the
  site of infection.
	 •	 Hypoalbuminaemia
	 	 Hypoalbuminaemia	 is	 likely	 to	 increase	 the	Vd	 and	 clearance	 of	 highly	 protein-bound	 antibiotics	 (e.g.
	 	 ceftriaxone,	cloxacillin,	ertapenem).	In	the	presence	of	increased	clearance,	the	increased	Vd still causes
	 	 a	 significant	prolongation	of	half-life	of	 the	antibiotic,	which	 is	beneficial	 for	 sustaining	concentrations
  throughout the dosing interval for highly susceptible pathogens. However, the decreased concentrations
	 	 from	 the	 increased	Vd	 may	 cause	 therapeutic	 failure	 against	 pathogens	 with	 higher	 MICs.	 In	 these
  situations, higher loading doses followed by an increase in frequency of administration or continuous
	 	 infusion	is	required	(Refer	to	Appendix B).
	 •	 Augmented	renal	clearance	
	 	 Augmented	 renal	 clearance	 (CrCl	 >	 130ml/min/1.73m2) is common in patients with sepsis, burns,
	 	 polytrauma,	traumatic	brain	injury	and	febrile	neutropenia.	Eight-hour	creatinine	clearance	may	be	done	
	 	 to	 confirm	 this.	 Significant	 correlations	 between	 subtherapeutic	 concentrations	 of	 beta-lactams	 or	
  vancomycin and augmented renal clearance were observed. Hence, the dose of antibiotics may have to 
  be increased and levels to be monitored.
4	 •	 Extracorporeal	therapies
  In patients with renal failure, the time to achievement of steady-state is increased for antibiotics cleared
	 	 by	the	kidneys.	In	addition,	patients	on	continuous	renal	replacement	therapy	(CRRT)	frequently	have	an
	 	 increased	Vd. Hence a loading dose is also necessary in these patients.
	 	 CRRT	 is	 effective	 at	 elimination	 of	 hydrophilic	 antibiotics	 especially	 those	 with	 low	 protein	 binding.
	 	 However,	the	amount	of	antibiotic	eliminated	depends	on	the	mode,	dose	of	CRRT	delivered,	blood	flow
	 	 rate,	filter	material	and	surface	area.	Like	CRRT,	antibiotic	pharmacokinetics	in	sustained	low-efficiency
	 	 dialysis	(SLED)	should	be	interpreted	with	knowledge	of	blood	and	dialysate	flow	rates,	treatment	duration
	 	 and	 filter	 surface	 area.	Time-dependent	 antibiotics	 are	more	 affected	 in	 SLED	 than	 in	 HD	 potentially
	 	 resulting	 in	prolonged	periods	of	concentration	below	MIC.	Hence,	 it	may	be	necessary	 to	administer
	 	 supplemental	 doses	 during	 or	 after	 SLED	 or	 prolong	 the	 infusion	 times.	 However,	 antibiotic	 dosing
	 	 guidelines	for	use	across	all	RRT	are	not	possible	because	of	widely	varied	drug	clearances	across	the
  different modalities and settings.
  There is limited data on optimal dosing for antibiotics in the presence of extracorporeal membrane
	 	 oxygenation	 (ECMO).	 Common	 mechanisms	 that	 influence	 pharmacokinetics	 during	 ECMO	 are
	 	 sequestration	 in	 the	 circuit,	 increased	 Vd, decreased drug elimination and direct adsorption to the
	 	 membrane.	Hydrophilic	antibiotics	with	a	small	Vd are prone to haemodilution and direct adsorption by the
	 	 membrane.	In	contrast,	lipophilic	and	highly	protein	bound	antimicrobials	(e.g.	voriconazole)	with	a	large
	 	 Vd are sequestered in the circuit.
55. De-escalation therapy
	 •	 De-escalation	refers	to	the	modification	of	an	empirical	antibiotic	regimen	to	an	alternate	regimen	with	a
  narrower spectrum of activity.
	 •	 Stop	 antibiotic	 therapy	 on	 day	 3	 if	 infection	 becomes	unlikely	 based	 on	 negative	 cultures	 and	 clinical
  course.
	 •	 De-escalate	the	empirical	antibiotic	regimen	once	the	aetiological	pathogen	is	identified.	
	 •	 Switch	to	monotherapy	after	3	to	5	days,	provided	that	the	initial	therapy	was	appropriate	and	the	clinical
	 	 response	was	good.	However,	be	cautious	if	resistant	organisms	with	high	in-vitro	MICs	are	isolated.
	 •	 Benefits	from	combination	therapy	have	been	inconsistent.
6. Shorten treatment duration
	 •	 Duration	of	antibiotic	therapy	can	be	shortened	to	7	days	for	most	patients	including	septic	shock,	based
  on therapeutic response and microbiological data. The exceptions are the immunosuppressed, those
  infected with multi-resistant organisms, those whose course deteriorates despite appropriate antibiotic or
  those whose initial therapy was inappropriate for the responsible organism.
	 •	 Studies	have	shown	that	procalcitonin-guided	therapy	resulted	in	shorter	duration	of	antibiotics	in	units
	 	 where	antibiotic	duration	exceeds	10	days.
7. Implement a structured antibiotic stewardship program
	 •	 Successful	 implementation	 requires	 an	 interdisciplinary	 team,	 educational	 interventions,	 system
  innovations, process indicator evaluation and feedback to health-care workers.
6	 •	 Refer	to	 ‘Protocol	on	Antimicrobial	Stewardship	Program	in	Healthcare	Facilities’	by	Ministry	of	Health
	 	 Malaysia,	First	Edition	2014.
Bibliography:
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7Antimicrobial agents are commonly used for prophylaxis or treatment of infections.
Prophylactic Antimicrobial Therapy
Antimicrobial	prophylaxis	(AP)	can	be	primary	(prevention	of	an	initial	infection),	secondary	(prevention	of	the	
recurrence of an infection) or for eradication of colonising organisms. It is often for surgical or nonsurgical 
indications.	Examples	of	nonsurgical	AP	include	prevention	of	infective	endocarditis	in	valvular	heart	disease	
undergoing dental procedures and prevention of infection by encapsulated organisms in asplenic patients.
Perioperative	antimicrobial	prophylaxis	is	to	prevent	surgical	site	infections	(SSI).	Optimal	agents	for	prophylaxis	
should	be	bactericidal,	inexpensive	and	active	against	the	typical	pathogens	that	can	cause	SSI	postoperatively.	
Intravenous	 prophylaxis	 should	 be	 given	within	 30	 to	 60	minutes	 before	 the	 surgical	 incision	 to	maximise	
its effectiveness. Giving more than one dose postoperatively is generally not advised except in prolonged 
procedures	 where	 risk	 of	 bacteraemia	 is	 present	 and	 in	 significant	 blood	 loss.	The	 practice	 of	 continuing	
prophylactic antibiotics is not recommended even if surgical drains are still insitu. 
Empirical Antimicrobial Therapy
Sepsis	in	the	critically	ill	remains	a	diagnostic	and	management	challenge.	Besides	adequate	fluid	resuscitation,	
vasopressor therapy and the support of the failing organ systems, the use of appropriate antimicrobial therapy 
and source control are equally important for good clinical outcomes. The aim of antimicrobial therapy is to 
achieve effective concentration at the target sites while minimising adverse events. 
PRINCIPLES OF ANTIMICROBIAL THERAPY
8In general, management of patients with suspected infection consists of initiation of empirical therapy followed 
by	targeted	therapy	once	microbiological	data	become	available.	Empirical	antibiotics	should	be	administered	
without delay. The decision for empirical therapy should be guided by the knowledge of the most likely site of 
infection and likely causative organisms. All appropriate microbiological specimens, including blood cultures, 
should be obtained before commencing therapy whenever possible. 
Inappropriate	and/or	delayed	antimicrobial	use	in	the	ICU	is	associated	with	poor	outcomes.	Moreover	this	can	
lead to the emergence of resistant organisms, antimicrobial-related adverse events and increase in healthcare 
costs. Antibiotic stewardship has been suggested to overcome these problems. 
When	initiating	empirical	antimicrobials	in	patients	with	sepsis,	consider	the	likely	organisms,	patient	factors	
and	antimicrobial	profiles.	
1. Likely causative organism
	 •	 Decide	if	community	or	nosocomial	infection.
	 •	 Identify	the	most	likely	source	of	infection.	
	 •	 Consider	local	epidemiological	data	and	laboratory-oriented	surveillance.	Knowing	the	resistance	profiles
  in the community, hospital or ICU helps in choosing antimicrobials appropriately.
	 •	 Evaluate	risk	factors	for	multidrug-resistant	(MDR)	organisms	e.g.	MRSA,	VRE	and	MDR	Gram-negative
  bacilli.
	 •	 Obtain	source	control	as	rapidly	as	is	practical	to	ensure	success	of	therapy.
92. Patient factors
	 •	 Exposure history
	 	 Take	a	travel	history	(e.g.	malaria	in	endemic	areas),	occupational	exposure	e.g.	rice	farmers	(Burkholderia
  pseudomallei),	fishermen	(Vibrio vulnificus),	intravenous	drug	users	(Staphylococcus aureus), activities in
	 	 contaminated	soil/water	(leptospirosis).
	 •	 Co-morbidities
	 	 Examples	in	diabetes	mellitus	(melioidosis),	chronic	lung	diseases	(Pseudomonas aeruginosa) and valvular
	 	 heart	diseases	(endocarditis).
	 •	 Severity of illness 
	 	 Patients	in	sepsis	and	septic	shock	require	emergent	and	broad-spectrum	antimicrobial	therapy.	Every	one
	 	 hour	delay	of	intravenous	antimicrobials	is	associated	with	significant	increased	mortality.
	 •	 Prior antimicrobial use or prolonged hospitalisation
	 	 Both	are	risk	factors	for	the	presence	of	resistant	organisms.
	 •	 Immunosuppressive states
	 	 Patients	 with	 underlying	 malignancy,	 post-splenectomy,	 unvaccinated,	 malnourished,	 on	 steroid	 or
  immunosuppressive drugs may require broad-spectrum therapy including antifungal. 
	 •	 Presence of renal or hepatic dysfunction
	 	 Drug	clearance	may	be	affected.	After	the	loading	dose,	adjust	maintenance	doses	and	intervals	to	the
	 	 severity	 of	 organ	 dysfunction.	The	 risk-benefit	 ratio	 of	 the	 antimicrobials	 must	 be	 determined	 on	 a
  case-to-case basis. 
10
	 •	 Pregnancy and lactation
  Ascertain the risk categories of antimicrobials in pregnancy.
	 •	 Others
  Adjust drug dosage in obesity and consider alternatives in drug allergies.
3. Antimicrobial profile
	 •	 Route of administration 
  The intravenous route should be used in severe infection as oral absorption is unpredictable even for drugs
	 	 with	good	oral	bioavailability.	In	addition	to	intravenous	administration;	 intrathecal	or	 inhalational	routes	
  may be considered to improve target site concentrations.
	 •	 Dose and interval 
	 	 Pathophysiological	changes	in	critically	ill	patients	alter	the	pharmacokinetic	(PK)	and	pharmacodynamic	
	 	 (PD)	 profile	 of	 the	 antimicrobials	 particularly	 volume	 of	 distribution	 (Vd) and clearance. ICU patients 
	 	 often	have	an	increased	Vd	for	hydrophilic	antibiotics.	Lower	antibiotic	concentrations	can	be	potentiated	
  by hypoalbuminaemia and augmented renal clearance for renally excreted drugs. Antibiotics can be 
	 	 categorised	 into	 three	different	classes	depending	on	 the	PK/PD	 indices	associated	with	 their	optimal	
  killing activity. Understanding exposure-effect relationships is required to optimise antibiotic dosing in the 
  critically ill.
11
	 •	 Achievable antimicrobial concentrations at target tissue
	 	 Dose	optimisation	strategies	should	be	taken	to	increase	the	antimicrobial	activities	at	the	target	sites	as
  illustrated in the table above.
  Aminoglycosides and glycopeptides penetrate tissues poorly. Aminoglycosides should not be used 
  as monotherapy while a higher plasma level of glycopeptides is recommended to ensure adequate tissue 
	 	 penetration.	Both	ß-lactams	and	quinolones	have	good	tissue	penetration.	Even	then	higher	doses	are	
  required to achieve adequate concentrations in infections of the central nervous system. Consider 
	 	 therapeutic	 drug	monitoring	 (TDM)	 of	 antibiotics	 to	minimise	 toxicity	 and	 also	 to	 prevent	 the	 risk	 of	
  treatment failure. 
MIC:	Minimum	Inhibitory	Concentration
PD kill characteristics
Time-dependent
(Refer	to	Appendix D)
Concentration-
dependent
Concentration-
dependent with time 
dependence
Optimal PK parameter
T>MIC
Percentage	of	time	where	drug	concentration	
remains	above	MIC	during	a	dosing	interval
Cmax/MIC
Ratio	of	peak	concentration	to	MIC	
AUC0-24/MIC
Ratio	 of	 area	 under	 concentration-time	 curve	
(AUC)	during	a	24-h	period	to	MIC
Goals of therapy/application
Maximise	duration	of	exposure	
> administer continuous infusion
Maximise	concentration	of	drug	
> use higher maintenance dose
Optimise	amount	of	drug	
> administer loading dose
Examples
Penicillins	
Cephalosporins
Carbapenems
Aminoglycosides
Polymyxin
Fluoroquinolones
Vancomycin
12
	 •	 Post antibiotic effect (PAE)
	 	 This	is	defined	as	persistent	suppression	of	bacterial	growth	even	after	the	serum	antibiotic	concentration	
	 	 falls	below	the	MIC	of	the	target	organism.	Aminoglycosides	and	fluoroquinolones	have	post-antibiotic	
  effect against Gram-negative bacteria.
	 •	 Adverse events
	 	 Risk-benefit	of	antimicrobials	with	potential	serious	adverse	events	should	be	considered	on	a	case-to-
	 	 case	basis.	If	unavoidable,	serum	levels	should	be	monitored	for	toxicity	(e.g.	aminoglycosides).
	 •	 Ecological profile
	 	 Limit	 the	 use	 of	 antimicrobials	 with	 potential	 for	 selecting	 resistant	 organisms	 e.g.	 third	 generation	
	 	 cephalosporins	result	in	selection	pressure	for	ESBL	producing	Enterobacteriaceae.
Empirical	therapy	should	be	re-evaluated	after	48-72	hours	or	when	culture	results	become	available.	Once	a	
causative	pathogen	is	identified,	narrow	the	spectrum	of	antimicrobial	therapy	(de-escalation).	Sensitivity	tests	
should	be	interpreted	carefully.	In	vitro	sensitivity	does	not	equate	with	clinical	effectiveness	(e.g.	ESCAPPM	
organisms: Enterobacter spp, Serratia spp, Citrobacter freundii, Aeromonas spp, Proteus vulgaris, Providencia 
spp, Morganella morganii).
If	the	patient	is	improving;	and	where	relevant,	definitive	source	control	has	been	achieved,	the	recommended	
duration	 of	 antimicrobial	 therapy	 is	 5-7	 days.	There	 is	 increased	 risk	 of	 resistance	 with	 prolonged	 use	 of	
antimicrobials. However, certain conditions may require prolonged therapy e.g. complicated Staphylococcus 
13
aureus infections, osteomyelitis, and infective endocarditis. Consider switching to the oral route whenever 
possible.
If	there	is	no	clinical	response	within	48-72	hours,	consider:
	 •	 possibility	of	a	secondary	infection.
	 •	 presence	of	resistant	organisms.
	 •	 inadequate	source	control	e.g.	abscesses	not	drained,	infected	prosthesis	not	removed.
	 •	 inadequate	penetration	of	antimicrobial	to	the	site	of	infection.
	 •	 inadequate	spectrum	of	antimicrobial	coverage.
	 •	 inadequate	dose	or	interval.
	 •	 non-infectious	 causes	 e.g.	 deep	 vein	 thrombosis,	 acute	 myocardial	 or	 pulmonary	 infarctions,	 acute
  pancreatitis, hyperthyroidism, Addisonian crisis, malignancies and central nervous system hemorrhages.
Bibliography:
1. Am J Respir Crit Care Med.	2016;	194(6):	681-91
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Identification	of	causative	organisms	is	central	to	effective	antimicrobial	therapy.	Whenever	possible,	appropriate	
cultures should always be obtained before commencing antimicrobials. 
Below	are	some	common	microbiological	investigations	that	are	relevant	to	the	intensive	care	practice.
Blood specimen
All	 septic	 patients	 (irrespective	 of	 source)	 should	 have	 blood	 cultures	 taken	 prior	 to	 commencement	 of	
antimicrobials.	Blood	cultures	must	be	taken	with	proper	skin	antisepsis	to	prevent	contamination	with	skin	
commensals	 (Corynebacterium spp and Propionibacterium spp).	Coagulase-negative	Staphylococcus	 (CoNS)	
isolated	 from	 peripheral	 blood	 alone	 is	 usually	 a	 contaminant.	 The	 recommended	 skin	 antiseptic	 is	 2%	
chlorhexidine	in	70%	isopropyl	alcohol.	A	venipuncture	is	the	preferred	site	and	collection	from	an	intravascular	
device	is	to	be	avoided	unless	for	the	purpose	of	diagnosing	catheter-related	bloodstream	infection	(CRBSI).	
Blood	cultures	from	devices	alone	have	increased	risk	of	contamination.
The	volume	of	blood	determines	the	yield	of	positive	result	 in	blood	culture.	A	minimum	of	20mls	of	blood	
should	be	drawn;	10mls	for	each	aerobic	and	anaerobic	bottle.	Increasing	the	volume	to	40-60mls	from	different	
venipuncture	 sites	 (obtaining	 2-3	 pairs	 of	 blood	 cultures)	 has	 been	 shown	 to	 increase	 the	 yield	 further.	 In	
suspected	endocarditis,	3	pairs	of	blood	cultures	taken	in	at	least	30-minute	intervals	are	required	to	confirm	
constant	bacteraemia	but	administration	of	antimicrobials	should	not	be	delayed	in	severely	ill	patients.	If	CRBSI	
is suspected simultaneous blood sampling from the peripheral blood and catheter hub need to be taken.
MICROBIOLOGICAL INVESTIGATIONS
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Blood	cultures	are	 routinely	 incubated	 for	5	days.	Longer	 incubation	 times	 if	HACEK	organisms,	Legionella, 
Brucella, Bartonella or Nocardia spp	are	suspected.	Incubation	up	to	4-6	weeks	is	needed	for	Mycobacterium 
tuberculosis.
When	disseminated	tuberculosis	(TB)	or	fungaemia	is	suspected,	BACTEC®	Myco/F	Lytic	culture	bottles	should	
be used to improve yield of these suspected organisms.
Blood	 can	 be	 taken	 for	 serological	 testing	 to	 diagnose	 atypical	 pneumonias,	 leptospirosis,	 melioidosis,	
toxoplasmosis, rickettsial and typhoid infections. 
Blood	tests	for	viral	infections	include	serology	for	herpes	simplex	type	1	and	2,	cytomegalovirus	(CMV),	dengue,	
measles,	 viral	 hepatitis	 and	 respiratory	 viruses.	 Consider	Human	 Immunodeficiency	Virus	 (HIV)	 serology	 in	
patients	at	risk.	Viral	cultures	are	not	routinely	performed.	
The	diagnosis	of	malaria	requires	3	sets	of	thick	and	thin	blood	smear	preparations	taken	over	a	48-hour	period	
(at	6,	12	and	48	hour).	In	smear	negative	patients	in	whom	malaria	is	still	strongly	suspected,	blood	for	malaria	
polymerase	chain	reaction	(PCR)	can	be	sent.
Respiratory specimen
A	good	specimen	of	sputum	or	tracheal	aspirate	for	Gram-stain	and	cultures	should	have	less	than	10	epithelial	
cells	per	low	power	field	reflecting	a	lower	respiratory	tract	sample.	Special	stains	can	be	requested	to	diagnose	
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Pneumocystis jiroveci or Mycobacterium tuberculosis.	Molecular	testing	by	PCR	for	MTB	DNA	and	rifampicin	
resistance	can	also	be	performed	(Xpert	Mycobaterium tuberculosis/Rifampicin).
Most	 laboratories	 report	 the	 results	 of	 sputum	 and	 tracheal	 aspirate	 cultures	 semi-quantitatively;	 either	 as	
light, moderate or heavy growth. A positive culture does not differentiate true pathogens from colonisers. 
Results	must	be	interpreted	in	the	context	of	the	clinical	condition	to	prevent	unnecessary	antimicrobial	use.	It	
is	adequate	to	use	tracheal	aspirate	semi-quantitative	cultures	to	guide	ventilator-associated	pneumonia	(VAP)	
therapy.	 If	quantitative	test	 is	available,	 the	threshold	for	diagnosing	VAP	with	tracheal	aspirate	 is	105	or	106 
colony	forming	units	(cfu)/ml.
Indications	 for	 bronchoalveolar	 lavage	 (BAL)	 or	 protected	 specimen	 brushing	 (PSB)	 include	 non-resolving	
pneumonia	and	for	diagnosis	of	diffuse	lung	infiltrates	in	the	immunocompromised	host.	BAL	or	PSB	need	to	
be	analysed	quantitatively	based	on	the	number	of	colony	forming	units	(cfu).	The	threshold	for	diagnosing	VAP	
with	BAL	is	104	or	105	cfu/ml	and	with	PSB	is	103	cfu/ml.	False	negatives	can	occur	if	sample	is	taken	during	
antibiotic therapy. 
Nasopharyngeal	swabs	and	the	above	respiratory	specimens	can	be	sent	using	appropriate	viral	transport	media	
for	viral	serology	and	PCR	tests.	Viral	cultures	are	not	routinely	performed.	The	viruses	commonly	investigated	
are	 influenza,	parainfluenza,	 respiratory	syncytial	 virus	 (RSV),	 adenovirus,	CMV	and	measles.	Viral	detection	
does not exclude concurrent bacterial infection.
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Of	 note,	 some	 respiratory	 infections	 can	 be	 diagnosed	with	 urinary	 specimens	 e.g.	 Legionella	 Serotype	 1	
(legionella	urinary	antigen	test)	and	pneumococcal	infections	(pneumococcal	urinary	antigen	test).
Pleural fluid specimen
In	diseased	conditions,	pleural	fluid	can	be	classified	into	exudate	or	transudate.	According	to	Light’s	criteria,	
pleural effusion is likely to be an exudate if at least one of the following exists: 
	 •	 Pleural	fluid/serum	protein	>	0.5	or	absolute	pleural	protein	>	30	g/L
	 •	 Pleural	fluid/serum	LDH	>	0.6	
	 •	 Pleural	fluid	LDH	level	>	two-thirds	upper	limit	of	normal	serum	value
A	parapneumonic	effusion	is	an	exudative	pleural	effusion	formed	secondary	to	pneumonia	(bacterial	or	viral)	or	
lung abscess, with a predominance of neutrophils.
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Parapneumonic effusion 
Characteristics of parapneumonic effusions
Characteristics
Appearance
Biochemistry
 pH
	 Glucose,	mmol/L
	 Ratio	of	pleural	fluid	
 to serum glucose
	 Lactate	
 dehydrogenase, 
	 U/L
Polymorphonuclear	
count,	cells/mL
Microbiological	test	
result
Treatment
Normal
clear
7.60	-	7.64
similar to plasma
1.0
<	50%	of	plasma	
<	1000	leucocytes/mm3
-
-
Uncomplicated
Clear, slightly turbid
>	7.30
>	3.3
>	0.5
<	700
<	15,000
Negative
Antibiotics
Complicated
Cloudy
<	7.20
<	2.2
<	0.5
>	1000
>	125,000
May	be	positive
Antibiotics and drainage
Empyema
Pus
NA
NA
NA
NA
May	be	positive
Antibiotics and drainage
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Characteristics of tuberculous pleural effusion
Characteristics
Appearance
Biochemistry	
 pH
	 Glucose,	mmol/L
	 Lactate	
	 dehydrogenase,	U/L
Leucocyte	count,
cells/mL
Acid-fast bacilli - Ziehl-
Neelsen	stain
Culture in solid media 
e.g.	Lowenstein-Jensen
Adenosine deaminase 
activity	(ADA)
Nucleic-acid	
amplification	e.g.	Xpert	
MTB/RIF	assay
Normal
clear
7.60	-	7.64
similar to 
plasma
<	50%	of	
plasma 
<	1000	
-
-
-
Tuberculous
straw-coloured
7.3	-	7.4
similar to plasma
>	500
1000	-	6000	predominantly	
lymphocytes	(usually	>75%)
positive	only	in	5%	
positive	in	12	-	30%	
>	40	U/L
(>95%	of	cases	are	tuberculous	in	
raised	ADA	when	associated	with	
lymphocytic pleural effusions)
low	sensitivity	(60	-	80%)
Notes
Turbid in chronic tuberculous empyema.
pH	<	7.20	indicates	more	of	chronic	tuberculous	empyema.
Low	glucose	concentration	is	more	characteristic	of	chronic	
tuberculous empyema.
Fluid	collected	in	the	first	few	days	may	exhibit	a	neutrophil	
predominant effusion.
Yields	are	higher	(>20%)	in:	
1.	HIV					2.tuberculous	empyema.	
Broth	medium	(e.g.	BACTEC)	provides	a	higher	yield	and	faster	
results.
Culture-positive	pleural	fluid	is	more	frequent	in	HIV-positive	
patients.
Also elevated in empyema, lymphoma, lung cancer, 
mesothelioma, leukaemia, brucellosis, Q fever, rheumatoid 
arthritis and systemic lupus erythematosis.
Usually	associated	with	a	positive	pleural	fluid	culture.
Xpert	MTB/RIF	test	on	pleural	fluid	does	not	accurately	
diagnose	pleural	TB.
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Cerebrospinal fluid specimen
Lumbar	 puncture	 should	 only	 be	 performed	 after	 a	 neurological	 examination	 but	 should	 never	 delay	 the	
administration of antimicrobials. A CT scan is indicated to rule out raised intracranial pressure prior to lumbar 
puncture. 
Cerebrospinal	fluid	(CSF)	should	be	analysed	within	an	hour	of	collection.	If	there	is	a	delay,	it	should	be	stored	
between	4-8°C.	Do	not	allow	CSF	to	sediment	before	partitioning	into	separate	tubes.
CSF analysis
Microscopy	and	stain	(Gram,	Indian	ink	and	Ziehl-Neelsen)
Biochemistry
Culture	and	sensitivity	(aerobic	and	anaerobic)
Latex	agglutination	test:
Streptococcus pneumoniae,	group	B	streptococcus,	Haemophilus influenzae	type	B,
Neisseria meningitidis	group	A,	B,	C,	Y	and	W135,	Escherichia coli	K1,	Listeria monocytogenes
Viral:	PCR	and/or	serology
Herpes	simplex	type	1	&	2,	varicella	zoster	virus,	Japanese	B	encephalitis	virus,	cytomegalovirus,	
Epstein-Barr	virus,	Nipah	virus,	human	herpesvirus	6,	enterovirus,	human	parechovirus	
Parasite	PCR
Toxoplasma gondii
Mycobacterium tuberculosis	PCR	and	culture
Fungal antigen and culture
Aspergillus fumigatus, Cryptococcus neoformans
Minimum volume (ml)
(may	vary	from	lab	to	lab)
1
1
2
1
3
3
10	
3
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Neutrophils	may	predominate
early in the illness.
Characteristics of CSF in CNS infections
Pressure,	cmH2O
Appearance
Protein,	g/L
Glucose,	mmol/L
CSF:serum	
glucose ratio
Lactate,	mmol/L
Cell	count/mm3
(predominant	cell	
type)
Notes
Normal
10-20
Clear
0.18-0.45
2.5-3.5
0.6
<	2.9
0-5	
lymphocytes	(70%)	
and 
monocytes	(30%)
Bacterial meningitis
>	30
Turbid
>	1.0
<	2.2
<	0.4
Q Q
>	1000
polymorphs
Partial	treatment	with	
antibiotics may alter 
CSF	parameters.
Neutropenics	
may not have 
characteristic 
polymorph responses 
in	the	CSF.
Viral meningitis/
encephalitis
N	or	Q
Clear
N	or	Q
N	or	M
>	0.6
N
5-1000
lymphocytes 
and monocytes
Tuberculous 
meningitis
Q
Fibrin web
1.0-5.0
1.6-2.5
<	0.5
Q
<	500
lymphocytes
Fungal 
meningitis
Q
Clear or turbid
0.2-5.0
M
<	0.5
Q Q
10-500
lymphocytes
Meningitis or ventriculitis 
in the presence of drains 
or shunts
-
Clear or turbid
N	or	Q
M
<	0.5
Q
>	15
polymorphs
WBC:	RBC	ratio	is	less	
than	1:100
(normal	1:500)
Cell	count	index	>	1
(ratio	WBC:	RBC	in	CSF	
to blood)
Positive	CSF	culture	may	
represent contaminant 
and clinical correlation is 
needed.
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The	standard	for	the	diagnosis	of	bacterial	meningitis	is	CSF	Gram	stain	and	culture.	Gram	stain	has	sensitivity	
between	60-90%,	provided	the	patient	has	not	received	antibiotics	prior	to	lumbar	puncture.	The	sensitivities	
of	CSF	culture	and	Gram	stain	decrease	after	antibiotic	 therapy.	Direct	antigen	 testing	or	polymerase	chain	
reaction	(PCR)	has	recognised	value	in	patients	with	clinical	findings	consistent	with	a	bacterial	CNS	infection	
who have negative Gram stain or culture results. 
PCR	assay	has	become	the	standard	for	detecting	viruses	associated	with	aseptic	meningitis	or	encephalitis.	
In	 some	cases,	 serological	 testing	may	be	more	 appropriate	 for	 suspected	arbovirus	 infections	 (West	Nile,	
St.	Louis	encephalitis,	Eastern	equine	encephalitis,	Japanese	encephalitis	viruses)	since	 immunocompetent	
patients	may	not	have	these	viruses	in	their	CSF	at	the	time	of	presentation.	
Urine specimen
Urine collection must be taken under aseptic technique to minimise the degree of bacterial contamination. The 
sample should be sent within an hour of collection since bacteria will continue to proliferate. Urine samples not 
sent	immediately	should	be	stored	at	4°C,	however	this	may	affect	leukocyte	counts.
If	the	patient	needs	catheterisation,	discard	the	first	few	mls	of	urine	and	collect	the	rest	in	the	sterile	container.	
If	the	patient	 is	already	catheterised,	clamp	the	catheter	and	clean	the	sampling	port	with	70%	alcohol	and	
collect	a	10ml	sample	of	urine.	Do	not	take	urine	samples	from	the	drainage	bag	due	to	high	risk	of	bacterial	
overgrowth leading to false positive results. In and out catheterisation for urine samples in an uncatheterised 
patient can be done. In patients on long-term catheters, replace the catheter before collecting specimens. 
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Most	cases	of	urinary	tract	infection	(UTI)	can	be	diagnosed	using	the	criteria	below.	Catheter-associated	UTI	
is	 the	presence	of	bacteriuria	 in	a	catheterized	patient	 (≥	48	hours)	who	has	signs	and	symptoms	 that	are	
consistent	with	UTI.	Pyuria	is	common	in	catheterised	patient	and	it	has	no	predictive	value.	
Routine	urine	culture	in	asymptomatic	catheterised	patient	is	not	
recommended.
Asymptomatic	significant	bacteriuria:
- a single specimen ≥	105	cfu/mL	
- specimen collected by in and out catheter ≥	102	cfu/mL
With 
catheter
Symptom
Present
Absent
Bacteriuria
cfu/mL
≥	103
Pyuria
WBC/mm3
Pyuria	is	common	
in patients with 
catheters. Its 
level has no 
predictive value.
No. of 
species
≤	2
Nitrite
undetected
Comments
Treat as UTI.
Replace	catheter	if	in	place	for	
>	7	days.
Treat	asymptomatic	significant	
bacteriuria in
•	 pregnancy
•	 prior	to	genitourinary
 manipulation
•	 post	renal	transplant	
•	 neutropenics
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Asymptomatic	significant	bacteriuria	if	2	consecutive	(>	24h	apart)	
mid-stream urine grows ≥	105	cfu/ml	of	the	same	bacterial	species	in	
women and ≥	103	cfu/ml	in	men.
Without 
catheter
Symptom
Present
Absent
Bacteriuria
cfu/mL
≥	103 in pregnant 
women and acute 
uncomplicated cystitis in 
women 
≥104 in acute 
uncomplicated 
pyelonephritis in 
women.
≥	104 in complicated UTI 
in men 
≥	105 in complicated UTI 
in women
Pyuria
WBC/mm3
>	10
No. of 
species
≤	2
Nitrite
detected
(only	positive	
in nitrite 
producing 
bacteria e.g. 
E. coli, Serratia 
spp, Klebsiella 
spp and 
Proteus spp)
Comments
Treat as UTI
For	definition	of	complicated	
and uncomplicated UTI refer 
to the chapter on genitourinary 
tract infection.
Treat	asymptomatic	significant	
bacteriuria in
•	 pregnancy
•	 prior	to	genitourinary	
 manipulation
•	 post	renal	transplant	
•	 neutropenics	
•	 urinary	obstruction	or	
 abnormal genitourinary tract
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Spontaneous	
bacterial 
peritonitis 
(SBP)
Culture 
negative 
neutrocytic 
ascites
Polymorphs 
count
(/mm3)
>	250
>	250
Bacterial 
culture
Positive	
(usually	1	type	
of organism) 
Poor	yield	for	
Gram-stain
Negative
Glucose 
mmol/L
>	2.7
NA
Protein
g/dL
<	1.0
NA
LDH
IU/L
<	225
NA
Treatment
Antibiotics
Treat	as	SBP
Notes
Inoculate	peritoneal	fluid	into	
blood culture bottles at bedside to 
improve sensitivity. 
Causes include: 
prior antibiotics, peritoneal 
carcinomatosis, pancreatitis, 
tuberculous peritonitis
Peritoneal fluid specimen 
Analysis	of	peritoneal	fluid	obtained	through	paracentesis	should	be	carried	out	to	determine	if	there	is	presence	
of	ascitic	fluid	infection	in	septic	patients	with	ascites.	Do	not	take	specimens	for	culture	from	in-situ	abdominal	
drains due to risk of contamination.
The	decision	to	begin	early	empirical	antibiotic	treatment	of	suspected	ascitic	fluid	infection	is	based	largely	on	
the	absolute	neutrophil	count	rather	than	the	culture,	which	takes	24-48	hours	to	demonstrate	growth.	
Characteristics of ascitic fluid infections
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Monomicrobial	
non-neutrocytic 
bacteriascites
Polymicrobial	
bacteriascites
Secondary	
bacterial 
peritonitis
Tuberculous 
peritonitis
Polymorphs 
count
(/mm3)
<	250
<	250
>	250	
(>	10,000	
WBC/ml)
150-4000	
WBC/ml
(>70%	
lymphocytes)
Bacterial 
culture
Positive	
(1	type	of	
organism)
Positive
(polymicrobial)
Positive
(polymicrobial)
-
Glucose 
mmol/L
NA
NA
<	2.7
Lower	
than 
serum
Protein
g/dL
NA
NA
>	1.0	
>	2.5
(SAAG	
< 1.1)
LDH
IU/L
NA
NA
>	225
>	90
Treatment
Treat	as	SBP	
in presence 
of sepsis
Antibiotics 
if develops 
peritonitis
Antibiotics 
and source 
control
-
Notes
May	be	early	stage	of	SBP.
In asymptomatic patients, repeat 
paracentesis.
Usually due to inadvertent 
puncture of the intestines during 
paracentesis.
Acid-fast	bacilli	-	Ziehl-Neelsen	
stain	is	positive	in	only	3%	of	
cases.
Stool specimen
Stool	 culture	 should	 not	 be	 done	 routinely	 in	 all	 patients	 presenting	 with	 diarrhoea	 unless	 in	 the	
immunocompromised,	elderly,	those	with	underlying	inflammatory	bowel	disease	and	with	severe	or	bloody	
diarrhoea.	Stool	samples	 for	ova	and	parasites	are	only	 recommended	 in	patients	with	persistent	or	bloody	
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diarrhoea or during waterborne outbreaks. Three specimens should be sent on consecutive days since parasite 
excretion may be intermittent. 
At least 5mls of diarrheal stool per rectal or per stoma is collected in a clean leak-proof container. The specimen 
should be transported to the laboratory and processed as soon as possible after collection. Culture of a single 
stool	specimen	has	a	sensitivity	of	>	95%	for	detection	of	the	enteric	bacterial	pathogen.	A	negative	culture	
for	Salmonella,	Campylobacter	and	Shigella	usually	rules	out	infection	by	these	organisms	as	excretion	of	these	
pathogens	is	continuous.	Repeat	specimens	are	not	required.
Stools	should	be	sent	for	Clostridium difficile toxin assay for patients who develop new onset of diarrhoea while 
in hospital. Clostridium difficile toxin detection falls into two categories of laboratory tests: organism detection 
assay	and	toxin	assay	[enterotoxin	(toxin	A)	and	cytotoxin	(toxin	B)].	Toxin	assays	available	are	cytotoxin	assay,	
enzyme	immunoassay	(EIA)	and	PCR.	EIA	is	the	preferred	diagnostic	assay	in	most	clinical	laboratories	because	
the	technique	is	relatively	simple	and	inexpensive	with	results	available	within	24	hours.	However,	because	of	
high	false	negative	rates,	three	consecutive	samples	are	recommended.	Positive	organism	detection	without	
toxin	 detection	does	not	 require	 treatment	 because	 this	 represents	 colonisation.	Only	 one	 stool	 sample	 is	
required for diagnosis of Clostridium difficile	with	PCR.	
Wound swabs
Wound	infections	should	be	diagnosed	clinically.	Chronic	wounds	have	colonised	microorganisms	but	this	does	
not	necessarily	mean	that	the	wound	is	infected.	Wounds	should	only	be	cultured	when	signs	and	symptoms	
of a deep infection are present. Culturing uninfected wounds may only be used as part of an infection control 
surveillance protocol. 
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Wound	 culture	 and	 susceptibility	 testing	 may	 be	 done	 using	 a	 swab,	 tissue	 biopsy	 or	 needle	 aspiration.	
Needle	aspiration	and	tissue	biopsy	are	preferred	methods	of	specimen	collection,	however	swab	cultures	are	
acceptable	as	they	are	practical,	non-invasive	and	cost	effective.	Wound	infection	occurs	in	viable	wound	tissue;	
therefore viable wound tissue must be swabbed rather than necrotic tissue or pus. At least 1cm2 area of viable 
tissue is required.
To obtain wound swabs, clean the wound with sterile saline to irrigate purulent debris and ensure that skin 
around	 the	wound	 is	 cleaned.	Moisten	 the	 swab	with	 sterile	 saline	 to	 increase	 the	 adherence	of	 bacteria.	
Rotate	the	swab	while	moving	it	across	the	entire	wound	in	a	zigzag	manner.	Alternatively	Levine’s	technique	
can be used where one rotates the swab over 1cm2 of the cleansed wound exerting enough pressure to 
express	exudates	from	within	the	tissue.	Once	collected,	promptly	send	the	swabs	obtained	to	the	laboratory	
in an appropriate transport media.
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Community-acquired pneumonia (CAP) is associated with significant morbidity and mortality, particularly in the 
elderly and those with chronic diseases. Management should be guided by clinical judgement and severity of 
pneumonia. High severity CAP e.g. CURB-65 score of 3 to 5 carries a mortality risk of 15% to 40%.
Aetiologic pathogens remain unidentified in 35 to 70% of cases. Empirical therapy should be started after 
considering patients’ risk factors for certain organisms e.g. patients with chronic lung disease are at higher 
risk of Pseudomonas aeruginosa pneumonia. In Asia, CAP caused by Gram-negative rods and Staphylococcus 
aureus were identified in higher proportions compared to the West, with Mycobacterium tuberculosis and 
Burkholderia pseudomallei reported as important causes.
Combination therapy with ß-lactams and macrolides has been shown to achieve better outcomes in patients 
with severe CAP. This combination confers broader coverage as a proportion of bacteraemic pneumococcal 
pneumonias have concomitant mycoplasma and rarely legionella infections. ß-lactams act on the bacterial wall 
while macrolides inhibit protein synthesis providing a dual mechanism of action. Apart from its antimicrobial 
activity, macrolides have anti-inflammatory properties and bacterial protein inhibition that result in less 
production of virulence factors.
Most patients with CAP show clinical improvement within 72 hours of initial antibiotic treatment. In those 
not responding to therapy, consider complications such as empyema or lung abscess or other causative
COMMUNITY-ACQUIRED PNEUMONIA
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Antimicrobials 
micro-organisms e.g. viruses, mycobacteria and fungi. Also consider possible non-infectious conditions 
e.g. congestive heart failure, pulmonary embolism, neoplasm, sarcoidosis, drug reaction and pulmonary 
haemorrhage.
Although recent RCTs and meta-analysis support the use of steroids in severe pneumococcal CAP, there is no 
clear mortality benefit. Moreover, the use of steroids has to be weighed against the risk of adverse effects. 
Likely Organisms
Streptococcus
 pneumoniae
Haemophilus 
 influenzae
Klebsiella 
 pneumoniae
Mycoplasma 
 pneumoniae
Legionella
 pneumophilia
Chlamydophila
 pneumoniae
Preferred
IV Amoxycillin/Clavulanate 
1.2g q8h
X 5-7 days
PLUS
IV Azithromycin 
500mg q24h
X 3-5 days
Alternative
IV Ceftriaxone
2g loading dose, 1g q12h 
X 5-7 days
PLUS
IV Azithromycin 
500mg q24h 
X 3-5 days
Notes
The indiscriminate use of 3rd generation cephalosporins 
may promote the emergence of ESBL producers.
If pneumococcal pneumonia is confirmed, deescalate 
to IV benzylpenicillin 4 million units q6h if MIC for 
penicillin is < 2mcg/ml. The emergence of drug 
resistant S. pneumoniae is on the rise.
A longer duration of therapy may be indicated if:
•	 initial	therapy	was	not	active	against	identified
 pathogen
•	 infection	at	extrapulmonary	sites	(meningitis,	
 endocarditis) is present
•	 causative	organism	is	P. aeruginosa, S. aureus, 
 Legionella spp or B. pseudomallei
•	 empyema	or	lung	abscess	is	present
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Antimicrobials 
Likely Organisms
Staphylococcus
 aureus
Preferred
PLUS OPTIONAL
(if MSSA suspected)
IV Cloxacillin 
2g q4h
X 10-14 days
Alternative
PLUS OPTIONAL
(if CA-MRSA suspected) 
IV Vancomycin 
15-20mg/kg q12h
OR 
IV Linezolid 
600mg q12h
X 10-14 days
Notes
Duration of treatment for confirmed atypical infections:
•	 Mycoplasma:	azithromycin	5	days	or	fluoroquinolone
 7 days
•	 Chlamydophila:	azithromycin	7-10	days.	Add
 doxycycline if not responding. 
•	 Legionella:	fluoroquinolone,	azithromycin	or	
 doxycycline :
 if immunocompetent for 7-10 days 
 if immunocompromised up to 3 weeks
Suspect S. aureus in the presence of necrotising 
cavitatory infiltrates or empyema, in intravenous drug 
users and post influenza.
CA-MRSA pneumonia is uncommon in Malaysia.
For loading dose and monitoring of vancomycin refer 
to Appendix C.
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Antimicrobials 
Likely Organisms
Pseudomonas 
 aeruginosa
Burkholderia 
 pseudomallei
Pneumocystis 
 jiroveci
Preferred
IV Piperacillin/Tazobactam 
4.5g q6h
OR 
IV Cefepime 
2g q8h
X 7 days
Refer to chapter on 
Melioidosis
IV Trimethoprim/
Sulfamethoxazole
5mg/kg (TMP component) 
q8h-q6h
X 21 days
Alternative
IV Imipenem 
1g q8h 
OR 
IV Meropenem 
1g q8h
X 7 days
IV Pentamidine 4mg/
kg/day 
OR
PO Primaquine 
30mg q24h
PLUS
IV Clindamycin 
900mg q8h
X 21 days
Notes
Risk factors are severe structural lung disease (e.g. 
bronchiectasis), COPD and steroid use .
If P. aeruginosa is sensitive to ceftazidime, consider 
de-escalation.
Dual therapy with aminoglycosides may be considered in:
•	 neutropenics
•	 CAP	with	bacteraemia
•	 septic	shock
Prednisolone should be given 15-30 min before 
antimicrobials.
PO prednisolone 40mg q12h x 5 days, then 40mg 
q24h x 5 days, then 20mg q24h x 11days.
Consider IV methylprednisolone (75% of prednisolone 
dose) if unable to tolerate orally.
Patients at risk:
•	 HIV	infection	with	CD4+	cells	<	200/µL
•	 HIV	infection	with	other	opportunistic	infections	e.g.	
 oral thrush
•	 on	long	term	immunosuppressive	or	chemotherapy	
•	 primary	immunodeficiency	disorder
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Antimicrobials 
Likely Organisms
Viral pneumonia
Influenza A
Influenza B
Parainfluenza 
viruses
Respiratory 
syncytial virus
Adenovirus
Coronavirus 
(SARS, MERS)
Varicella zoster 
 virus
Herpes simplex 
 virus
Preferred
T. Oseltamivir 
75mg q12h
X 5 days
No antiviral of proven 
value 
IV Acyclovir 
10mg/kg q8h 
X 7 days
Alternative
Notes
Influenza virus types A and B account for more than 
50% of all community-acquired viral pneumonias in 
adults.
Influenza virus impairs T lymphocytes, neutrophil 
and macrophage function. A high clinical suspicion 
of bacterial superinfection with S. aureus or S. 
pneumoniae should be maintained.
Critically ill patients may have prolonged influenza 
viral replication in the lower respiratory tract. Consider 
longer therapy regimens, if illness is prolonged.
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Aspiration may result in chemical pneumonitis or aspiration pneumonia. The usual causative organisms in 
aspiration pneumonia are those that colonise the oropharynx. Risk factors for aspiration are conditions that 
suppress cough and mucociliary clearance. In community-acquired cases, oral anaerobes are the predominant 
organisms related to poor dentition or oral care and periodontal disease. Hospitalised and institutionalised 
patients are more likely to have oropharyngeal colonisation with Gram-negative enteric bacilli and Staphylococcus 
aureus.
Antimicrobials are not indicated in aspiration without evidence of infection. However, consider antibiotics in 
chemical pneumonitis if the pneumonitis fails to resolve within 48 hours, in patients with small bowel obstruction 
or on acid suppression therapy.
Lung abscess is defined as liquefactive necrosis of the pulmonary parenchyma and formation of cavities caused 
by microbial infection. It is considered primary lung abscess when it results from existing parenchymal process 
and is termed secondary when it complicates another process (e.g. vascular emboli). Common causes include:
	 •	 aspiration	pneumonia	
	 •	 severe	necrotising	pneumonia	due	to	S. aureus and K. pneumoniae
	 •	 septic	emboli	from	right	sided	endocarditis	(tricuspid	valve	endocarditis)	
	 •	 suppurative	(septic)	thrombophlebitis	of	internal	jugular	veins	(Lemierre’s	syndrome)
Attempts should be made to identify the causal organisms by obtaining bronchoscopic specimens and pleural 
fluid for cultures. Drainage of the abscess via a percutaneous catheter is recommended.
ASPIRATION PNEUMONIA AND LUNG ABSCESS
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Community-acquired aspiration pneumonia/lung abscess
Healthcare-associated aspiration pneumonia/lung abscess
Antimicrobials 
Likely Organisms
Anaerobes: 
 Peptostreptococci
 Fusobacterium spp
 Prevotella melaninogenica
 Bacteroides spp 
  (not Bacteroides fragilis)
Streptococcus pneumoniae
Haemophilus influenzae
Staphylococcus aureus
Enterobacteriaceae
Moraxella catarrhalis
Enterobacteriaceae 
Pseudomonas aeruginosa 
Staphylococcus aureus
Anaerobes
Preferred
IV Amoxicillin/
Clavulanate 
1.2g q8h
OR
IV Ampicillin/Sulbactam
3g q6h
IV Piperacillin/
Tazobactam 
4.5g q6h
Alternative
IV Ceftriaxone 2g 
loading dose,
1g q12h
PLUS
IV Clindamycin 
600mg q8h
IV Imipenem 
1g q8h
OR
IV Meropenem 
1g q8h
Notes
Oral anaerobes are sensitive to ß-lactam/ß-lactamase 
inhibitors. Metronidazole is added to Cefriaxone to 
cover Prevotella melaninogenica.
Clindamycin is preferred in the severely ill or as a 
substitute in patients with unfavorable or delayed 
response. 
Duration of treatment:
•	 Aspiration	pneumonia	X	7	days
•	 Lung	abscess	minimum	4	weeks	depending	on	the	
 causative organism, clinical response or resolution 
 by CT scan.
Duration of treatment: 
•	 Aspiration	pneumonia	X	7	days
•	 Lung	abscess	minimum	4	weeks	depending	on	the	
 causative organism, clinical response or resolution 
 by CT scan.
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Lung abscess secondary to Lemierre’s syndrome
Lung abscess secondary to tricuspid valve endocarditis
Others
Antimicrobials 
Likely Organisms
Anaerobes
Fusobacterium spp
Eikenella corrodens 
Porphyromonas 
 asaccharolytica 
Streptococcus spp 
Bacteroides
Methicillin-sensitive 
Staphylococus aureus
Methicillin-resistant 
Staphylococcus aureus
Burkholderia pseudomallei
Preferred
IV Amoxycillin/
Clavulanate
1.2g q8h
OR
IV Ampicillin/Sulbactam 
3g q6h 
Refer to chapter on 
Infective Endocarditis
Refer to chapter on 
Melioidosis
Alternative
IV Piperacillin/
Tazobactam 
4.5g q6h 
Notes
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Hospital-acquired pneumonia (HAP) is defined as pneumonia that occurs 48 hours or more after hospitalisation 
while ventilator-associated pneumonia (VAP) is pneumonia that occurs after 48 hours following intubation. The 
term healthcare-associated pneumonia is no longer used because patients’ contact with healthcare system is 
no longer considered a significant risk factor for multidrug-resistant (MDR) pathogens.
The single risk factor for MDR HAP is prior antibiotic use within 90 days. However the risk factors for MDR VAP 
include: prior antibiotic use within 90 days, septic shock at time of VAP, ARDS preceding VAP, five or more days 
of hospitalisation prior to occurrence of VAP and acute renal replacement therapy prior to onset of VAP.
The prevalence of causative organisms varies from unit to unit, hence empirical antibiotics must reflect local 
microbiological data. MDR organisms are increasing in frequency most notably the MDR Gram-negative 
organisms. In MRIC Report 2015, Gram-negative organisms accounted for 90.7% of VAP organisms and 60% 
were MDR organisms. Acinetobacter spp, Klebsiella spp and Pseudomonas aeruginosa constituted 65%, 
24.8% and 4.9% of MDR strains respectively. Staphylococcus aureus comprises 8.1% of VAP organisms, 75% 
being methicillin-resistant organisms. 
A positive respiratory specimen culture does not differentiate true pathogens from colonisers. Results must be 
interpreted in the context of the clinical condition to prevent unnecessary antimicrobial use. Candida pneumonia 
is very uncommon and only ever seen in severely immunocompromised patients following haematogenous 
spread. This needs tissue confirmation.
HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED PNEUMONIA
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The treatment and management of ventilator-associated tracheobronchitis (VAT) requires further research. 
Treatment for VAT may be instituted if deemed necessary to reduce sputum production and facilitate weaning 
from mechanical ventilation after considering the risks of excess antibiotic use and adverse effects.
Recent evidence has demonstrated that duration of antibiotics could be shortened to 7 days even for MDR 
Pseudomonas aeruginosa and Acinetobacter baumanii organisms. Duration of treatment for MRSA pneumonia 
is 10 to 14 days. Longer duration may be indicated depending upon clinical, radiologic and laboratory parameters. 
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Empirical treatment in patients with HAP or VAP without risk factors for MDR pathogens
Empirical treatment in patients with HAP or VAP with risk factors for MDR pathogens
Antimicrobials 
Likely Organisms
Streptococcus 
 pneumoniae
Haemophilus 
 influenzae
Staphylococcus 
 aureus
Klebsiella 
 pneumoniae
Pseudomonas 
 aeruginosa
Klebsiella 
 pneumoniae 
Pseudomonas 
 aeruginosa
Haemodynamically stable
IV Amoxycillin/Clavulanate
1.2g q8h
OR
IV Cefuroxime
1.5g q8h
OR
IV Ceftriaxone 
2g loading dose, 1g q12h
IV Piperacillin/Tazobactam 
4.5g q6h 
OR
IV Cefepime
2g q8h
Haemodynamically unstable
IV Piperacillin/Tazobactam 
4.5g q6h 
OR
IV Cefepime 
2g q8h
IV Imipenem 
1g q8h 
OR
IV Meropenem 
1g q8h
Notes
Consider Piperacilin/Tazobactam or Cefepime 
in patients with chronic lung disease due to 
increased risk of P. aeruginosa infections.
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Empirical treatment in patients with VAP with risk factors for MDR pathogens
Antimicrobials 
Likely Organisms
Acinetobacter 
 baumanii (44.6%*)
Klebsiella 
 pneumoniae 
 (20.3%)
Pseudomonas 
 aeruginosa (15.1%)
Methicillin-resistant
Staphylococcus 
 aureus (6.4%)
*Data from MRIC 
Report 2015
Haemodynamically stable
IV Ampicillin/Sulbactam 
9g q8h 
PLUS OPTIONAL
IV Piperacillin/Tazobactam 
4.5g q6h
OR
IV Cefepime 
2g q8h
PLUS OPTIONAL
IV Vancomycin 
15-20mg/kg q12h
OR
IV Linezolid
600mg q12h
Haemodynamically unstable
IV Polymyxin E 
Loading dose and 
12 hours later 4.5 million 
units q12h 
PLUS OPTIONAL
IV Imipenem 
1g q8h 
OR
IV Meropenem 
1g q8h
PLUS OPTIONAL
IV Vancomycin 
15-20mg/kg q12h
OR
IV Linezolid
600mg q12h
Notes
Sulbactam component of 9g is required. Refer to 
Appendix D for dilution.
The incidence of MDR Acinetobacter in VAP is 
87%. Although the empirical use of polymyxin 
may increase the frequency of appropriate 
therapy, it will potentiate polymyxin resistance 
and increase drug toxicity rates. Hence the 
recommendation to use polymyxin only if patient 
is unstable.
For loading dose of polymyxin refer to Appendix A.
Consider MRSA cover if
•	 Antibiotic	usage	90	days	prior	in	a	unit	known	
 to have more than >10% causative MRSA 
 organism 
•	 The	 patient	 is	 MRSA	 colonised	 with	 a	 high	
 quality tracheal aspirate Gram Stain showing 
 numerous and predominant GPC in clusters 
For loading dose and monitoring of vancomycin 
refer to Appendix C.
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Pathogen specific
Acinetobacter baumanii
MDR Acinetobacter 
 baumanii
Klebsiella pneumoniae 
Escherichia coli
(non ESBL-producing)
Antimicrobials
IV Ampicillin/Sulbactam
9g q8h
IV Polymyxin E
Loading dose and 12 hours later
4.5 million units q12h 
PLUS OPTIONAL (in VAP)
Inhaled Polymyxin E
1 million units q8h
IV Amoxycillin/Clavulanate
1.2g q8h
OR
IV Cefuroxime
1.5g q8h
OR
IV Ceftriaxone
2g loading dose, 1g q12h
Notes
Sulbactam component of 9g is required. Refer to Appendix 
D for dilution.
Inhaled polymyxin may be used as an adjunct to IV polymyxin 
in patients unresponsive to IV polymyxin. Optimal dosing 
remains undefined. Modes of nebulisation and ventilator 
settings need to be addressed to ensure effective delivery.
Nebulise salbutamol 15 minutes prior.
For loading dose of polymyxin refer to Appendix A.
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Pathogen specific
Klebsiella pneumoniae
Escherichia coli
(ESBL-producing)
Klebsiella pneumoniae
Escherichia coli
(carbapenem-resistant)
Antimicrobials
IV Ertapenem
1g q24h
OR
IV Imipenem
1g q8h
OR
IV Meropenem
1g q8h
IV Polymyxin E
Loading dose and 12 hours later
4.5 million units q12h
PLUS OPTIONAL (in VAP)
Inhaled Polymyxin E 1 million units q8h
Notes
Among the carbapenems, ertapenem is less likely to 
induce carbapenem resistance in Acinetobacter spp and
P. aeruginosa. 
Inhaled polymyxin may be used as an adjunct to IV polymyxin 
in patients unresponsive to IV polymyxin. Optimal dosing 
remains undefined. Modes of nebulisation and ventilator 
settings need to be addressed to ensure effective delivery.
Nebulise salbutamol 15 minutes prior.
For loading dose of polymyxin refer to Appendix A.
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Pathogen specific
Pseudomonas aeruginosa
Pseudomonas aeruginosa
(group 1 ß-lactamase)
Antimicrobials
IV Ceftazidime
2g q8h
OR
IV Piperacillin/Tazobactam
4.5g q6h
OR
IV Cefepime
2g q8h
PLUS OPTIONAL
IV Amikacin
15mg/kg/q24h X 3-5 days
OR
IV Ciprofloxacin
400mg q8h X 7 days
IV Imipenem
1g q8h
OR
IV Meropenem
1g q8h
PLUS OPTIONAL
IV Amikacin
15mg/kg/q24h X 3-5 days
OR
IV Ciprofloxacin
400mg q8h X 7 days
Notes
Combination therapy for pseudomonal infection has not 
been shown to be superior to monotherapy.
Dual therapy may be considered In septic shock and those 
unresponsive to therapy.
In VAP, if P. aeruginosa is only sensitive to aminoglycoside, 
use both IV and inhaled amikacin 400mg q8h. Optimal 
dosing remains undefined. Modes of nebulisation and 
ventilator settings need to be addressed to ensure effective 
delivery.
45
Pathogen specific
Pseudomonas aeruginosa
(carbapenem resistant)
Methicillin-sensitive 
Staphylococcus aureus
Methicillin-resistant
Staphylococcus aureus
Antimicrobials
IV Polymyxin E
Loading dose and 12 hours later
4.5 million units q12h
PLUS OPTIONAL (in VAP)
Inhaled Polymyxin E 1 million units q8h
IV Cloxacillin
2g q4h
IV Vancomycin
15-20mg/kg q12h
OR
IV Linezolid
600mg q12h
Notes
Inhaled polymyxin may be used as an adjunct to IV polymyxin 
in patients unresponsive to IV polymyxin. Optimal dosing 
remains undefined. Modes of nebulisation and ventilator 
settings need to be addressed to ensure effective delivery.
Nebulise salbutamol 15 minutes prior.
For loading dose of polymyxin refer to Appendix A.
For loading dose and monitoring refer to Appendix C.
Consider Linezolid in necrotising pneumonia.
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Pathogen specific
Stenotrophomonas 
 maltophilia
Burkholderia cepacia
Antimicrobials
IV Trimethoprim/Sulfamethoxazole 
5mg/kg (TMP component) q8h X 10-14 
days
IV Trimethoprim/Sulfamethoxazole 
5mg/kg (TMP component) q8h X 10-14 
days
Notes
Carbapenem therapy is associated with the emergence of 
these organisms.
Consider combination therapy with ceftazidime or 
meropenem in severe infections
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Tuberculosis (TB) is caused by Mycobacterium tuberculosis, which may affect pulmonary and/or extra-pulmonary 
sites. It is transmitted via the airborne route. Patients at risk of TB infections include:
	 •	 the	 immunocompromised	 (e.g.	malnutrition,	HIV,	diabetes	mellitus,	 renal	 failure,	 silicosis,	 drug	abuse,	
  alcohol abuse, steroid and tumour necrosis factor-α inhibitor use) 
	 •	 close	contact	with	a	person	with	infectious	TB	disease
	 •	 migrants	from	areas	with	high	rates	of	TB
	 •	 groups	with	high	rates	of	TB	transmission	e.g.	the	homeless,	HIV	patients	and	injecting	drug	users	
	 •	 persons	who	work	or	reside	with	people	who	are	at	high	risk	of	TB	in	facilities	or	institutions	e.g.	hospitals,	
  prisons.
The aim of treatment is to cure and render patients non-infectious, prevent relapse and emergence of resistant 
tubercle bacilli. Treatment duration is a minimum of 6 months in pulmonary, abdominal, pleural, pericardial and 
lymph nodes infections. However may increase up to 9-12 months in TB meningitis, spine and joint infections, 
the immunocompromised and those with drug resistant TB.
The current drug regimen involves the four main drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol. 
The 6-month treatment regime involves an intensive phase of 8 weeks and a continuation phase of 4 months.
TUBERCULOSIS
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Treatment phase
Intensive
Continuation 
Preferred agent
Ethambutol/Isoniazid/Rifampicin/
Pyrazinamide q24h 
X 8 weeks 
or 56 daily doses
Isoniazid/Rifampicin daily
X 4 months
or 126 doses
Notes
Streptomycin can be used if
•	 Ethambutol	is	contraindicated
•	 In	the	presence	of	severe	liver	impairment
PO pyridoxine 20-50mg q24h should be given to prevent isoniazid-
induced neuropathy. Higher dose for patients with increased risk 
e.g. pregnancy, diabetics, malnourished, alcoholics, renal failure 
and advanced age.
It is necessary to consult the TB specialist if: 
•	 Relapse,	treatment	failure	or	treatment	after	interruption.
•	 Liver	failure.
•	 Unable	 to	 tolerate	oral	medications.	Parenteral	options	 include	
 isoniazid, rifampicin, aminoglycosides and fluoroquinolones.
•	 Co-infection	with	HIV.
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Drug
Tab Isoniazid 
Tab Rifampicin 
Tab Ethambutol 
Tab Pyrazinamide 
IM/IV Streptomycin 
Fixed Dose 
Combination (FDC)
4 FDC
e.g. AKuriT-4
3 FDC
e.g. AKuriT-3
e.g. Rimcure 3FDC or 
AKuriT Z
Dose
5 (4-6) mg/kg/day
10 (8-12) mg/kg/day
15 (15-20) mg/kg/day
25 (20-30) mg/kg/day
15 (12-18) mg/kg/day
Content
Rifampicin 150mg, Isoniazid 75mg, 
Ethambutol 275mg, Pyrazinamide 
400mg
Rifampicin 150mg, Isoniazid 75mg, 
Ethambutol 275mg, 
Rifampicin 150mg, Isoniazid 75mg, 
Pyrazinamide 400mg
Max. dose
300mg
600mg
1.6g
2g
1g
Adverse reaction
hepatitis, peripheral neuritis, hypersensitivity, skin rash
hepatitis, vomiting, thrombocytopenia, skin rash
optic neuritis, gastrointestinal disturbances
hepatotoxicity, hyperuricemia, skin rash
nephrotoxicity, ototoxicity, skin rash
Patients > 65 years old, dose should not exceed 750mg
Dose based on body weight (4 FDC/3 FDC)
30-37kg: 2 caps q24h
38-54kg: 3 caps q24h
55-70kg: 4 caps q24h
>70kg: 5 caps q24h
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Steroids in TB
Conditions
TB Meningitis
TB Adrenalitis
TB Pericarditis
Steroid Dose
IV Dexamethasone 0.4mg/kg/day taper 
over 6-8 weeks
IV Hydrocortisone 100mg q8h and taper
PO Prednisolone 120mg q24h, taper 
over 6-12 weeks
Notes
Weak evidence. Only consider in those with highest risk of 
inflammation (large pericardial effusions or early signs of 
constrictive pericarditis).
In HIV patients use of steroids in pericarditis has been 
associated with increased risk of cancers.
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Acute infective diarrhoea is usually self-limiting, requiring only supportive management, and is commonly 
caused by viral pathogens like norovirus and rotavirus. The presence of severe abdominal pain in a patient older 
than 50 years of age or peritoneal signs with ileus on examination should lead to a workup for more serious 
intraabdominal disease rather than attributing it to infective diarrhoea.
Treatment with anti-microbials are usually not recommended for mild to moderate disease except in cases of 
bacteraemia and in the immunocompromised patients. Antimicrobials are also indicated for severe disease 
associated with extremes of age, gross blood in stool, high grade fever and persistent symptoms for more than 
one week. Some can lead to serious sequelae like renal failure following haemolytic-uraemic syndrome due to 
Escherichia coli 0157:H7 and Guillan-Barre syndrome following Campylobacter diarrhoea.
ACUTE INFECTIVE DIARRHOEA
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Empirical therapy: non bloody diarrhoea
Empirical therapy: bloody diarrhoea
Antimicrobials 
Likely Organisms
Salmonella typhi
Salmonella non-typhi
Enterotoxigenic
Escherichia coli (ETEC)
Vibrio cholera
Shigella dysenteriae
Enterohaemorrhagic
 Escherichia coli
  0157 (EHEC)
Entamoeba
 histolytica
Preferred
IV Ceftriaxone 
3g q24h
PLUS
OPTIONAL
IV Azithromycin 
1g single dose
OR
PO Doxycycline
300mg single dose
IV Ceftriaxone 
3g q24h 
PLUS OPTIONAL
IV Metronidazole 
500mg q8h
Alternative
IV Ciprofloxacin
400mg q12h
IV Ciprofloxacin 
400mg q12h
Notes
Duration of therapy in salmonellosis
•	 Immunocompetent	X	7	to	10	days
•	 Immunocompromised	minimum	14	days
If E. coli 0157 is isolated, stop antibiotics and observe for 
haemolytic uraemic syndrome (HUS).
If S. dysenteriae is isolated, duration of therapy: 
•	 Immunocompetent	X	3	days
•	 Immunocompromised	X	7	 to	10	days	 (if	bacteraemic	
 minimum 14 days)
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Clostridium difficile infection (CDI)
CDI occurs predominantly in hospitalised patients because of antibiotic usage leading to the disturbance of 
normal intestinal microbiota. Culprit antibiotics include clindamycin, cephalosporins, quinolones and penicillin.
It is suspected when patients present with watery diarrhoea, associated with fever (T > 38.5°C) and abdominal 
pain. CDI may present as ileus. Diagnosis is made by the detection of C. difficile toxin in the stools. Colonoscopy 
finding of pseudomembranous colitis may aid diagnosis when laboratory confirmation is delayed or negative, or 
when presentation is atypical. Offending antibiotics should be discontinued if possible. 
Relapse occurs in up to 27% of cases, typically between 3 days to 3 weeks after treatment is discontinued. 
Patients are known to excrete C. difficile for weeks following recovery which may present as an infection control 
challenge.
Metronidazole should not be used after the first recurrence. Fidaxomicin has been shown to be effective in 
reducing relapse rate in mild to moderate cases but use in severe disease cannot be recommended. Faecal 
microbiota transplant is a treatment option.
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Severity of illness
First episode:
Mild to moderate
Severe 
Severe Complicated
Antimicrobials
PO Metronidazole 
400mg q8h 
X	10	days
PO Vancomycin
125mg q6h
X	10-14	days
PO Vancomycin*
125mg q6h
PLUS
IV Metronidazole 500mg q8h
PLUS OPTIONAL
Rectal Vancomycin 500mg q6-8h 
(dilute in 100mls Normal saline)
X	10	days
Notes
White cell count (WBC) < 15 x 109/L and serum creatinine < 1.5x 
baseline
WBC >15 x 109/L and serum creatinine > 1.5 x baseline plus albumin 
< 25g/L, elevated lactate
•	 IV	formulation	of	Vancomycin	can	be	given	orally	as	the	intravenous
 form is not effective.
•	 When	 unable	 to	 tolerate	 oral	 Vancomycin	 adequately	 follow	
 regimen for severe complicated CDI. 
Lab results as above plus clinical deterioration e.g. shock with 
peritonitis or pseudomembranous colitis on colonoscopy. 
*Some experts advocate a higher dose of oral Vancomycin at 500mg 
q6h especially in severe cases though an added mortality benefit of 
a higher dose was not seen. 
Indications for surgery include: 
•	 Toxic	megacolon	or	bowel	perforation
•	 Severe	deterioration	despite	optimal	antibiotic	therapy
55
Bibliography:
1. Clin Micro Inf: 2013 (Suppl. 2), 1-26
2. N Eng J Med: 2014 370; 16
3. Int Med Journal: 2016: doi: 10.1111/imj.13027 pg 479-493 ASID 
 updated guidelines for the management of Clostridium difficile 
 infection in adults and children in Australia and New Zealand
Severity of illness
First recurrence
Second recurrence
Antimicrobials
As per first episode
Tapering and pulsed oral
Vancomycin 125mg PO q6h for 7-14 
days then
125mg PO q12h for 7 days then
125mg PO q24 for 7 days then
125mg PO every other day for 7 
days then 
125mg PO every 3 days for 14 days
Notes
Recurrent CDI: When CDI reoccurs within 8 weeks after resolution 
of symptoms from the previous episode.
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Infectious complications in severe acute pancreatitis are associated with considerable morbidity and mortality. 
Prophylactic antibiotics are not effective in reducing the incidence of pancreatic infection and thus are not 
recommended. The use of antibiotics in patients with sterile necrosis to prevent the development of infected 
necrosis is also not recommended. 
The timing of infection is variable but peaks in the second to fourth week after the onset of pancreatitis.
The probability of infection is partly related to the extent of pancreatic necrosis. Infected pancreatic necrosis 
(IPN) should be considered in patients with pancreatic necrosis who deteriorate or fail to improve after 7-10 days 
of hospitalisation. A CT scan finding of gas in the pancreas is diagnostic of IPN. In these patients, empirical use 
of antibiotics is recommended, with or without a CT-guided fine-needle aspiration for Gram stain and culture. 
These antibiotics should penetrate pancreatic necrosis well e.g. ß- lactams (ceftazidime, cefepime, piperacillin-
tazobactam), carbapenems, quinolones and metronidazole. Antifungal coverage should be considered, 
especially if multiple risk factors for invasive candidiasis are present.
Pancreatic abscess is often a late complication of acute necrotising pancreatitis occurring more than 4 weeks 
later. Many of these respond to percutaneous or endoscopic drainage and antibiotics.
ACUTE INFECTIVE PANCREATITIS
57
Antimicrobials 
Likely Organisms
Enterobacteriaceae
(Escherichia coli 
Klebsiella spp
Proteus spp)
Enterococcus spp
Bacteroides spp 
Candida albicans
Candida non albicans
Preferred
IV Piperacillin/Tazobactam
4.5g q6h
OR
IV Cefepime 2g q8h
PLUS
IV Metronidazole 500mg q8h
PLUS OPTIONAL
IV Fluconazole
D1 800mg 
followed by 400mg q24h
Alternative
IV Imipenem
1g q8h
OR
IV Meropenem
1g q8h
PLUS OPTIONAL
IV Anidulafungin
D1 200mg
followed by 100mg q24h
OR
IV Caspofungin
D1 70mg 
followed by 50mg q24h
OR
IV Micafungin
100mg q24h
OR
IV Lipid formulation 
Amphotericin B
3-5mg/kg q24h
OR
IV Amphotericin B
0.6-1mg/kg/day
Notes
Duration of treatment is guided by 
repeated clinical and serial radiological 
assessments.
Consider echinocandins if patient has 
had recent azole exposure in the past 
3 months.
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Acute cholangitis can be a life-threatening infection secondary to biliary obstruction and stasis. The common 
causes are biliary calculi, benign stenosis and malignancy. It is also a common complication of stent placement 
for malignant biliary obstruction. The causative organisms are commonly Gram-negative and occasionally 
polymicrobial including anaerobes. This may result from translocation of bacteria from the portal system or 
duodenum into the biliary tree. Besides antimicrobial therapy, prompt drainage of the biliary tract need to be 
considered.
Acute cholecystitis is primarily an inflammatory process and secondary infection of the gall bladder can occur 
as a result of cystic duct obstruction and bile stasis. Antimicrobial therapy is instituted in the presence of 
leukocytosis or fever, and radiologic findings indicative of gallbladder rupture or necrosis. Antimicrobials are also 
recommended in patients of advanced age, diabetics or the immunocompromised. Obstruction to bile flow may 
prevent biliary excretion resulting in the inability to achieve adequate concentrations of antibiotic there.
BILIARY SEPSIS
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Antimicrobials 
Likely Organisms
Enterobacteriaceae
(Escherichia coli, 
Klebsiella spp, 
Enterobacter spp)
Enterococci
Pseudomonas
 aeruginosa
Anaerobes
(Bacteroides fragilis, 
Clostridium 
 perfringens)
Preferred
IV Cefoperazone 
2g 12qh
PLUS
IV Metronidazole
500mg q8h
Alternative
IV Piperacillin/
Tazobactam 
4.5g q6h
OR
IV Cefepime 
2g q8h
PLUS
IV Metronidazole
500mg q8h 
OR
IV Imipenem
1g q8h
OR
IV Meropenem
1g q8h
Notes
Consider the alternative regime in healthcare-associated biliary 
sepsis (e.g. patients with recent ERCP, presence of stents or 
entero-biliary surgery). 
Consider enterococcal cover in the immunocompromised (solid 
organ transplant or steroid therapy), and patients with valvular heart 
disease, intravascular prosthetic devices or previous antimicrobial 
use.
Ceftriaxone may increase biliary sludging.
Duration of therapy:
•	 Post	cholecystectomy	following	acute	cholecystitis	X	1	day
•	 Post	 cholecystectomy	 for	 perforated,	 emphysematous	 or	
	 necrosis	of	the	gall	bladder	X	4-7	days
•	 Acute	cholangitis	with	source	of	infection	controlled	X	4-7	days
•	 Bacteraemia	 with	 Enterococcus spp, Streptococcus spp	 X	
 minimum 2 weeks
•	 Presence	of	residual	stones	or	obstruction,	treat	until	anatomical	
 problems are resolved
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Liver abscess is classified by aetiology into pyogenic (80%), amoebic (10%) and fungal abscess (10%). Pyogenic 
abscess is the most common and may occur following spread through the biliary tree, by extension of adjacent 
infection, haematogenous dissemination, trauma or following instrumentation e.g. chemoembolisation or 
biliary sphincterotomy. Invasive Klebsiella pneumoniae liver abscess syndrome (KLAS) is a community-acquired 
primary liver abscess that may have metastatic manifestations (endophthalmitis, meningitis, brain abscess). 
Abscess caused by Burkholderia pseudomallei should be considered in patients who present with shock. 
Tuberculous liver abscesses are uncommon but should be considered when typical pyogenic organisms are 
not recovered from cultures. 
Amoebic liver abscess may be seen in patients who are from or have visited endemic areas. Serological test is 
positive for most patients with amoebic liver abscess. Fungal liver abscess is usually due to Candida albicans 
and occurs in patients on immunosuppressive therapy. 
Besides antimicrobial therapy, drainage of the abscess may be required. Pyogenic liver abscess will require 4-6 
weeks of antimicrobial therapy, and drainage of abscess needs to be considered. Amoebic liver abscess will 
require 7-10 days of antimicrobial therapy followed by a luminal agent for eradication of gut colonisation. 
LIVER ABSCESS
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PLUS
IV Metronidazole 500mg q8h
Antimicrobials 
Likely Organisms
Enterobacteriaceae 
(Escherichia coli 
Klebsiella 
 pneumoniae)
Streptococcus milleri
Enterococcus spp
Staphylococcus 
 aureus
Anaerobes
(Bacteroides spp 
Fusobacterium spp 
Actinomyces spp 
Clostridium spp)
Entamoeba 
 histolytica
Preferred
IV Ceftriaxone 
2g loading dose,
1g q12h
Alternative
IV Piperacillin/Tazobactam 
4.5g q6h
OR
IV Cefepime 
2g q8h
OR
IV Meropenem 
1g q8h
OR
IV Imipenem 
1g q8h
Notes
Consider alternative therapy if haemodynamically 
unstable. Consider carbapenem when melioidosis is 
suspected or recent history of antibiotic use.
Consider anti-fungal therapy in immunocompromised 
or neutropenic patients.
 
Entamoeba histolytica is not covered by ß-lactams or 
carbapenems
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Intra-abdominal infections (IAI) are usually classified as uncomplicated or complicated.  In uncomplicated IAI, 
the infection only involves a single organ (e.g. appendicitis, diverticulitis, cholangitis) and does not extend to 
the peritoneum. In complicated IAI, the infectious process extends beyond the organ, causing either localised 
peritonitis with abscess formation or diffuse peritonitis.
Diffuse peritonitis is classified into:
 1. Primary or spontaneous bacterial peritonitis (SBP): infection is usually caused by a single organism without 
  loss of integrity of the gastrointestinal tract; typically seen in cirrhotic patients with ascites. 
 2. Secondary peritonitis: infection resulting from loss of integrity of the gastrointestinal tract or from infected 
  viscera. 
 3. Tertiary peritonitis: persistent or recurrent infection that typically occurs at least 48 hours after apparently 
  successful source control of secondary peritonitis. 
IAIs can be further classified into community-acquired or healthcare-associated IAIs. Empiric antimicrobials with 
a narrower spectrum of activity are adequate in patients with community-acquired IAI. Healthcare-associated 
IAIs are associated with higher risk for multi-drug resistant organisms.
The treatment of IAI involves both timely source control and empiric antimicrobial therapy. Post-operative 
antimicrobial therapy need not be continued in uncomplicated IAI following source control (e.g. acute appendicitis). 
In complicated IAIs, antimicrobials are usually continued after source control. The duration of therapy should 
PERITONITIS
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be shortened in patients with a positive response (usually 4-7 days), except in cases of immunosuppression or 
ongoing infections. Prolonged antibiotic therapy does not prevent subsequent infectious complications, which 
is more often due to progression of the original disease or inadequate original source control. However, for 
patients in whom source control is known to be suboptimal, the optimal duration of antibiotic treatment is 
uncertain and decisions on treatment duration must be made on a case-by-case basis.
Spontaneous bacterial peritonitis
Antimicrobials 
Likely Organisms
Escherichia coli
Klebsiella 
 pneumoniae
Streptococcus 
 pneumoniae
Enterococci
Staphylococcus 
 aureus
Preferred
IV Cefotaxime 
2g q8h
OR
IV Ceftriaxone 
2g loading dose, 
1g q12h 
X	5	days
Alternative
IV Meropenem 
1g q8h
OR
IV Imipenem 
1g q8h
PLUS OPTIONAL
IV Vancomycin
15-20mg/kg q12h 
X	5	days
Notes
Consider alternative therapy to cover for ESBL-producing 
organisms and MRSA if the patient has risk factors for 
multi-resistant infections e.g.
•	 nosocomial	origin	of	infection	
•	 on	fluoroquinolone	prophylaxis	
•	 recent	infection	with	multi-resistant	bacteria	
•	 recent	use	of	ß-lactam	antibiotics	
Metronidazole is not indicated as anaerobes are rarely 
the causative organism in SBP.
For loading dose and monitoring of vancomycin refer to 
Appendix C.
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Community-acquired complicated IAI
Antimicrobials 
Likely Organisms
Escherichia coli
Klebsiella
 pneumoniae
Streptococcus milleri
Bacteroides spp
Preferred
IV Ceftriaxone 
2g loading dose, 
1g q12h
OR
IV Cefoperazone 
2g q12h
PLUS 
IV Metronidazole 
500mg q8h
Alternative
IV Piperacillin/
Tazobactam
4.5g q6h
OR
IV Cefepime
2g q8h
PLUS
IV Metronidazole
500mg q8h
OR
IV Meropenem
1g q8h
OR
IV Imipenem 
1g q8h
OR
IV Doripenem
500mg q8h
Notes
Consider alternative therapy in patients at high risk for 
mortality or with risk factors for infection with multi-
resistant bacteria.
Factors associated with high risk for mortality are:
•	 age	>	70	years
•	 delay	in	initial	intervention	>	24	hours
•	 inability	to	achieve	adequate	source	control
•	 comorbidity	(renal	or	liver	disease,	malignancy,	
 malnutrition)
•	 immunocompromised	
•	 high	severity	of	illness
•	 severe	peritoneal	involvement	or	diffuse	peritonitis
Consider carbapenems against ESBL-producing bacteria 
in patients with the following risk factors:
•	 recent	exposure	to	antibiotics	(esp.	ß-lactams	or	
 fluoroquinolones) within 90 days 
•	 colonisation	with	ESBLs
•	 where	MDR	Enterobacteriaceae	is	widespread	in	the	
 community
Anti-MRSA agents or anti-fungals are not recommended 
in the absence of evidence of such infection.
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PLUS OPTIONAL
IV Vancomycin
15 - 20 mg/kg q12h
PLUS OPTIONAL
Healthcare-associated complicated IAI
Antimicrobials 
Likely Organisms
ESBL-producing 
Enterobacteriaceae:
(Escherichia coli
Klebsiella 
 pneumoniae 
Enterobacter spp 
Proteus spp)
Pseudomonas
 aeruginosa
Acinetobacter spp
Enterococci
Anaerobes
Methicillin-resistant
Staphylococcus
 aureus
Preferred
IV Piperacillin/
Tazobactam 
4.5g q6h
OR
IV Cefepime
2g q8h
PLUS
IV Metronidazole
500mg q8h
PLUS OPTIONAL 
IV Ampicillin
2g q6h
Alternative
IV Meropenem 
1g q8h
OR
IV Imipenem 
1g q8h
OR
IV Doripenem 
500mg q8h
PLUS OPTIONAL
IV Ampicillin
2g q6h
Notes
Consider carbapenems in patients who are 
haemodynamically unstable or at risk for infection with 
ESBL-producing bacteria:
•	 recent	exposure	to	antibiotics	(esp.	ß-lactams	or	
 fluoroquinolones) within 90 days
•	 colonisation	with	ESBLs
•	 where	MDR	Enterobacteriaceae	is	prevalent	
Consider anti-enterococcal agent (ampicillin or 
vancomycin) in these patients:
•	 on	prolonged	cephalosporins
•	 immunocompromised
•	 valvular	heart	disease	
•	 prosthetic	heart	valves	or	prosthetic	intravascular	
 devices
•	 recurrent	IAI
Consider anti-MRSA in those colonised with MRSA, prior 
MRSA treatment failure or significant antibiotic exposure. 
For loading dose and monitoring of vancomycin refer to 
Appendix C.
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Antimicrobials 
Likely Organisms
Candida albicans
Candida non-albicans
Preferred
IV Fluconazole 
D1 800mg 
followed by 
400mg q24h
Alternative
IV Anidulafungin 
D1 200mg 
followed by 
100mg q24h
OR
IV Caspofungin 
D1 70mg 
followed by 
50mg q24h
OR 
IV Micafungin 
100mg q24h
OR 
IV Lipid formulation 
Amphotericin B 
3-5mg/kg q24h 
OR
IV Amphotericin B 
0.6-1mg/kg q24h
Notes
Consider anti-fungal in patients with:
•	 recurrent	gastro-duodenal	perforations
•	 anastomotic	leaks
•	 necrotising	pancreatitis
•	 no	clinical	improvement	despite	on	antibiotics
Fluconazole should be the first-line anti-fungal in 
haemodynamically stable patients who are colonised 
with azole susceptible Candida or have no prior exposure 
to azoles.
Consider alternative anti-fungals (echinocandins 
or amphotericin B and its lipid formulations) in 
haemodynamically unstable patients or those previously 
exposed to azoles.
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Urinary tract infections (UTI) can manifest from asymptomatic bacteriuria to severe sepsis. 
Complicated UTI usually refers to an infection that occurs in a patient with a structural or functional abnormality, 
impeding urine flow, or in a host with altered defences or in patients with metabolic disorders like diabetes or 
azotemia. Antimicrobial resistance is more common and failure of therapy is higher even with agents active 
against the causative pathogens. UTI in males is considered complicated. 
Urosepsis implies clinically evident severe infection of the urinary tract and may be associated with shock and 
multi-organ dysfunction. Complicated UTI is the commonest precursor of urosepsis. Patients at higher risk 
for developing urosepsis include the elderly, diabetics and immunosuppressed patients and renal transplant 
patients. Drug treatment of urosepsis often has to be complemented with endoscopic and/or surgical 
intervention.
Ultrasound scan is especially valuable for emergency imaging in patients presenting with urosepsis. It is helpful 
in defining kidney and ureteric size, and in evaluation of the prostate plus other various complications of acute 
pyelonephritis such as emphysematous pyelonephritis, renal abscess and perirenal abscess and to rule out 
obstructive uropathy.
 
Sterile pyuria is common in catheterised patients and does not warrant treatment. Catheter-associated urinary 
tract infection (CAUTI) is defined as the presence of bacteriuria (> 103 cfu/ml) in a catheterised patient (≥ 48 
URINARY TRACT INFECTION
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hours) who has signs and symptoms consistent with UTI. CAUTI should be treated with antimicrobials and 
the catheter changed (if more than a week) or removed. Treatment duration for CAUTI varies from 7-21 days 
depending on organism, comorbid conditions and clinical response. In asymptomatic catheterised patients with 
significant bacteriuria (> 105 cfu/ml), treatment is indicated only in patients who are neutropenic, pregnant, 
undergoing genitourinary tract manipulation or post renal transplant.
Lower UTI or Acute Uncomplicated Pyelonephritis
Antimicrobials 
Likely Organisms
Escherichia coli 
Klebsiella spp
Proteus mirabilis
Preferred
IV Amoxycillin/
Clavulanate 
1.2g q8h
OR
IV Ampicillin/
Sulbactam 
3g q6h
X 10 days
Alternative
IV Cefuroxime 
1.5g q8h
OR
 
IV Ceftriaxone 
2g loading dose,
1g q12h 
X 10 days
Notes
Duration of treatment for uncomplicated cystitis is 3-5 
days.
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Acute Complicated Pyelonephritis
Antimicrobials 
Likely Organisms
Escherichia coli 
Klebsiella spp
Proteus mirabilis
Pseudomonas
 aeruginosa 
Citrobacter spp
Enterobacterteriacae
 (ESBL)
Enterococcus spp
Preferred
Antibiotic naïve
IV Amoxycillin/
Clavulanate 
1.2g q8h
OR
IV Ampicillin/
Sulbactam 
3g q6h
OR
IV Ceftriaxone
2g loading dose,
1g q12h
X 14-21 days
Alternative
Recent antibiotic 
exposure
IV Piperacillin/
Tazobactam 
4.5g q6h
OR
IV Cefepime 
2g q8h
OR
IV Imipenem 
1g q8h
OR
IV Meropenem 
1g q8h 
OR
IV Doripenem 
500mg q8h
X 14-21 days
Notes
Enterococcal infections are more likely in patients post 
abdominal surgery, liver transplantation and prosthetic 
heart valves and vascular grafts. Use ampicillin/
vancomycin for enterococcal infections. 
Use of ciprofloxacin is associated with increased 
incidence of resistant strains.
Obstructive uropathy should be sought and relieved. 
Switch to oral therapy when possible to complete course.
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Acute Complicated Pyelonephritis (cont’d)
Antimicrobials 
Likely Organisms
Candida albicans
Candida spp
Preferred
Antibiotic naïve
IV Fluconazole 
400mg q24h
X 14-21 days
Alternative
Recent antibiotic 
exposure
IV Amphotericin B 
0.3-0.6mg/kg q24h
X 14-21 days
Notes
Candiduria is often asymptomatic and is a common 
coloniser. Treat only prior to urinary tract instrumentation 
or if neutropenic. Remove indwelling catheter if possible.
When infection is suspected use alternative antifungals 
if:
•	 recent	azole	exposure	in	the	last	3	months
•	 known	to	be	colonised	by	azole-resistant	Candida spp
Echinocandins and lipid formulations of Amphotericin B 
do not achieve adequate urine concentrations, and are 
not useful for CAUTI but can be used for pyelonephritis.
Amphotericin B bladder irrigation in 50 mg/L sterile water 
daily for 5 days, may be useful for treatment of cystitis 
due to fluconazole-resistant species, such as C. glabrata 
and C. krusei.
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Renal Abscess
Antimicrobials 
Likely Organisms
Enterobacteriaceae 
Methicillin-sensitive
Staphylococcus 
 aureus 
Methicillin-resistant
Staphylococcus 
 aureus
Preferred
Treat as acute 
complicated 
pyelonephritis 
IV Cloxacillin 
2g q4h 
IV Vancomycin 
15-20mg/kg q12h
Alternative
IV Linezolid 
600mg q12h
Notes
Corticomedullary and perinephric abscesses 
are commonly due to ascending infections by 
enterobacteriacae.
Consider image- guided aspiration or surgical drainage of 
abscess.
Renal cortical abcesses are usually due to haematogenous 
spread of S. aureus. They are often multiple and not 
drainable.
Duration of therapy should be prolonged. 
For loading dose and monitoring of vancomycin refer to 
Appendix C.
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Catheter-related bloodstream infection (CRBSI) refers to bloodstream infection attributed to an intravascular 
catheter. It is diagnosed when the same organism with the same antibiogram is grown from paired blood 
samples (peripheral vein and catheter lumen) with any of the following criteria:
1. quantitative cultures of blood samples with a 3-fold greater colony count in the catheter than the peripheral 
 sample
2. differential time to positivity of 2 hours: growth from the catheter lumen is detected at least 2 hours earlier 
 than the periphery in an automated blood culture system.
This section deals only with CRBSI associated with short-term central venous catheters (CVC).
A patient with short-term CVC is suspected to have catheter-related infection if there is fever, chills and/or 
hypotension and no apparent source for the bloodstream infection except the catheter. Presence of catheter 
site inflammation alone does not always indicate CRBSI and vice versa. 
After appropriate cultures are taken, empirical intravenous antimicrobial therapy should be initiated based on 
the severity of illness, underlying disease and the potential pathogens. In the Malaysian Registry of Intensive 
Care Report 2015 and 2016, Gram-negative organisms predominate at 68.2% and 54.6% respectively. Thus, 
antibiotic coverage against Gram-negative bacteria is recommended in the empirical treatment of CRBSI in our 
ICUs. 
CATHETER-RELATED BLOODSTREAM INFECTION
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Following diagnosis of CRBSI, short-term CVC must be removed as soon as possible with the exception of 
coagulase-negative staphylococcus (CoNS) as the causative pathogen. Catheter removal is warranted in the 
presence of severe sepsis, haemodynamic instability, endocarditis or evidence of metastatic infection, erythema 
or exudate due to suppurative thrombophlebitis or persistent bacteraemia after 72 hours of antimicrobial 
therapy to which the organism is susceptible. Catheter salvage with antibiotic lock therapy is generally not 
recommended for short-term CVCs.
Echocardiography should be performed at least 1 week after the onset  of bacteraemia or fungaemia in patients 
with CRBSI who have prosthetic valve or implantable cardiac device. It is also indicated in patients with 
persistent bacteraemia or fungaemia after 3 days of initiation of appropriate antimicrobial and catheter removal. 
Repeat echocardiography in patients with a high index of suspicion for infective endocarditis in whom the initial 
findings were negative. 
CRBSI is classified as complicated when there is persistent bacteraemia or fungaemia despite CVC removal 
and appropriate therapy; or presence of suppurative thrombophlebitis, metastatic foci of infection (e.g. infective 
endocarditis, septic arthritis, osteomyelitis, epidural abscess, septic emboli). Systemic antibiotics should be 
continued for 4-6 weeks and for 6-8 weeks in osteomyelitis. 
The effectiveness of antibiotic or antiseptic-impregnated catheters in reducing CRBSI in ICUs remains to be 
studied in large clinical trials. In units where CRBSI rates remain high despite implementation of comprehensive 
preventive measures to reduce infection, these catheters may be recommended for use in adult patients who 
are expected to have CVCs in-situ for more than five days.
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Empirical therapy in patients with CRBSI
Antimicrobials 
Likely Organisms
Gram-negative bacilli
Klebsiella spp
Acinetobacter spp
Pseudomonas 
 aeruginosa
Escherichia coli 
Coagulase-negative
Staphylococcus
Staphylococcus 
 aureus
(Methicillin sensitive 
or resistant)
Enterococcus
 faecalis 
(Ampicillin sensitive 
or resistant)
Enterococcus
 faecium
(Vancomycin 
sensitive or resistant)
Preferred
IV Cefepime 
2g q8h
OR
IV Piperacillin/
Tazobactam
4.5g q6h
PLUS
IV Cloxacillin 
2g q4h
Alternative
IV Meropenem 
1g q8h
OR 
IV Imipenem
1g q8h 
PLUS
IV Vancomycin 
15-20mg/kg q12h
PLUS OPTIONAL 
IV Polymyxin E
Loading dose and 
12 hours later
4.5 million units q12h 
Notes
Consider alternative therapy in patients who are 
haemodynamically unstable or immunocompromised. 
Antibiotic coverage for MDR gram-negative bacilli should 
be considered in patients with neutropenia, severe 
sepsis, or colonised with such pathogens.
Consider MRSA cover in patients with prosthetic valves 
or vascular grafts, prior antibiotic use, on haemodialisis, 
prolonged hospital stay, HIV or reside in nursing homes.
Risk factors for candida CRBSI include parenteral 
nutrition, femoral catheters, prolonged use of broad-
spectrum antibiotics, haematological malignancy, bone 
marrow or solid organ transplant and candida colonisation 
at multiple sites. 
For loading dose of polymyxin refer to Appendix A.
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Empirical therapy in patients with CRBSI (cont’d)
Antimicrobials 
Likely Organisms
Candida albicans
Candida
 non- albicans
Preferred
PLUS OPTIONAL
IV Fluconazole 
D1 800mg 
followed by
400mg q24h
Alternative
PLUS OPTIONAL
IV Anidulafungin 
D1 200mg 
followed by
100mg q24h
OR
IV Caspofungin 
D1 70mg 
followed by 
50mg q24h
OR
IV Micafungin 
100mg q24h
OR
IV Amphotericin B 
0.6-1mg/kg q24h
Notes
Fluconazole should be the first-line anti-fungal in 
haemodynamically stable patients who are colonised 
with azole susceptible Candida or have no prior exposure 
to azoles.
Consider alternative anti-fungals (echinocandins 
or amphotericin B and its lipid formulations) in 
haemodynamically unstable patients or those previously 
exposed to azoles.
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Pathogen specific
Antimicrobials 
Likely Organisms
Coagulase-negative 
staphylococcus 
(except 
Staphylococccus
 lugdunensis)
Methicillin sensitive
Methicillin resistant
Staphylococcus 
 aureus 
Staphylococcus 
 lugdunensis
Methicillin sensitive
Methicillin resistant
Preferred
IV Cloxacillin
2g q4h 
IV Vancomycin 
15-20mg/kg q12h
IV Cloxacillin
2g q4h
IV Vancomycin 
15-20mg/kg q12h
Alternative
Notes
Single positive cultures of CoNS should not be treated 
unless confirmed by follow-up cultures, the patient is 
immunosuppressed or critically ill, or the patient has 
implanted device e.g. prosthetic valves.
Duration of therapy (D1 is the first day on which blood 
cultures are negative):
•	 5-7	days	if	catheter	is	removed	(preferred)
•	 10-14	days	if	catheter	salvage	attempted
All patients with S. aureus CRBSI should have 
echocardiography performed to rule out endocarditis.
Duration of therapy (D1 is the first day on which blood 
cultures are negative):
•	 14	days	(minimum)
•	 4-6	weeks	in	haematogenous	complications	(e.g.	
 endocarditis, septic thrombosis)
•	 6-8	weeks	in	osteomyelitis
Linezolid should not be used as monotherapy to treat 
catheter-related MRSA bacteraemia.
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Pathogen specific
Antimicrobials 
Likely Organisms
Enterococcus
 faecalis
Enterococcus
 faecium
Ampicillin sensitive
Ampicillin resistant, 
vancomycin sensitive
Ampicillin resistant, 
vancomycin resistant
Escherichia coli 
Klebsiella spp
ESBL negative
ESBL positive
Preferred
IV Ampicillin 
2g q4h
IV Vancomycin 
15-20mg/kg q12h
IV Linezolid
600mg q12h
IV Ceftriaxone 2g 
loading dose, 1g q12h
IV Meropenem
1g q8h
OR
IV Imipenem
1g q8h
Alternative
IV Daptomycin 
10mg/kg q24h
Notes
Repeat cultures to confirm infection before starting 
treatment to rule out culture contamination.
Perform echocardiography to rule out endocarditis if there 
is persistent bacteraemia after 3 days on appropriate 
antibiotics, presence of a prosthetic valve or vascular 
device. 
Duration of therapy (D1 is the first day on which blood 
cultures are negative):
•	 7-14	days	
•	 4-6	weeks	in	presence	of	endocarditis	or	metastatic	
 infection
Duration of therapy (D1 is the first day on which blood 
cultures are negative): 7-14 days.
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Pathogen specific
Antimicrobials 
Likely Organisms
Pseudomonas
 aeruginosa 
Acinetobacter spp
Enterobacter spp
Serratia spp
Citrobacter spp
Proteus spp
Preferred
IV Piperacillin/
Tazobactam 4.5g q6h
OR
IV Cefepime 2g q8h
PLUS OPTIONAL
IV Amikacin 
15mg/kg/day 
X 3 days
IV Ampicillin/Sulbactam
9g q8h
IV Meropenem 
1g q8h
OR
IV Imipenem 
1g q8h
Alternative
IV Meropenem 1g q8h
OR 
IV Imipenem 1g q8h
PLUS OPTIONAL
IV Amikacin 
15mg/kg/day 
X 3 days
IV Polymixin E 
Loading dose and 12 
hours later 4.5 million 
units q12h
IV Cefepime 
2g q8h
Notes
Duration of therapy (D1 is the first day on which blood 
cultures are negative): 7-14 days.
Sulbactam component of 9g is required. Refer to 
Appendix D for dilution.
For loading dose of polymyxin refer to Appendix A.
Duration of therapy (D1 is the first day on which blood 
cultures are negative): 7-14 days.
Deescalate to cefepime if susceptible.
Duration of therapy (D1 is the first day on which blood 
cultures are negative): 7-14 days.
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Pathogen specific
Antimicrobials 
Likely Organisms
Stenotrophomonas 
 maltophilia 
Burkholderia cepacia 
Corynebacterium
 spp
Bacillus spp
Elizabethkingia spp
(previously known as 
Chryseobacterium
 spp)
Preferred
IV Trimethoprim/
Sulfamethoxazole
5mg/kg (TMP component) 
q8h
IV Trimethoprim/
Sulfamethoxazole
5mg/kg (TMP component) 
q8h
IV Vancomycin
15-20mg/kg q12h
Alternative
Notes
Duration of therapy (D1 is the first day on which blood
cultures are negative): 7-14 days 
Consider combination therapy with ceftazidime or 
meropenem in severe infections.
Duration of therapy (D1 is the first day on which blood
cultures are negative): 7-14 days 
Confirmation of CRBSI requires at least 2 positive 
percutaneous blood cultures for the same organism. A 
single set of positive blood culture does not prove true 
bloodstream infection.
Duration of therapy is tailored to clinical circumstances.
Antibiotics should be selected based on antimicrobial 
susceptibility testing on a case-by-case basis. 
Combination antibiotic is encouraged.
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Pathogen specific
Antimicrobials 
Likely Organisms
Candida albicans
Candida non albicans 
Preferred
IV Fluconazole 
D1 800mg 
followed by 400mg q24h
IV Anidulafungin 
D1 200mg 
followed by 100mg q24h
OR
IV Caspofungin 
D1 70mg 
followed by 50mg q24h
OR
IV Micafungin 
100mg q24h
Alternative
IV Amphotericin B 
0.6-1mg/kg q24h
OR
IV Lipid formulation 
Amphotericin B 
3 - 5mg/kg q24h
Notes
Echocardiography and abdominal ultrasound should 
be performed to exclude endocarditis or disseminated 
candidiasis, and fundoscopy to exclude endophthalmitis 
or chorioretinitis.
Duration of therapy (D1 is the first day on which blood 
cultures are negative):
•	 14	days	(without	metastatic	complication)
If there is metastatic complication, the duration should 
be based on the site, clinical improvement and resolution 
of lesions on imaging.
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Duke criteria is widely used for the diagnosis of infective endocarditis (IE). Prior to initiation of antibiotic therapy, 
at least three sets of blood cultures should be obtained from different venipuncture sites, with the first and last 
samples drawn at least 1 hour apart. An echocardiogram should be done in all suspected cases to confirm the 
diagnosis. Transoesophageal echocardiography (TEE) should be done if initial transthoracic echocardiography 
(TTE) images are negative. Culture-negative endocarditis can occur up to 31% of all cases of IE. This could be 
due to previous antimicrobial therapy, inadequate microbiological techniques or fastidious organisms.
Treatment is guided by presentation, clinical findings, native or prosthetic valves and organism virulence. Surgery 
is indicated in patients with high risk features (heart failure, uncontrolled infection, fungal infection, non HACEK 
gram-negative infections e.g. Pseudomonas aeruginosa, annular/aortic abscess) that make the possibility of 
cure with antibiotic treatment unlikely and those at high risk of embolisation (large mobile vegetations > 10mm). 
Blood cultures should be taken every 48 hours until the results are negative. Duration of treatment begins from 
the day of first negative culture.
INFECTIVE ENDOCARDITIS
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Empirical therapy
Antimicrobials 
Likely Organisms
Native valve
Preferred
IV Ampicillin 
2g q4h
PLUS
IV Gentamicin
3mg/kg q24h 
PLUS OPTIONAL 
IV Cloxacillin 
2g q4h
Alternative
IV Cefriaxone 
2g loading dose,
1g q12h
PLUS OPTIONAL
IV Cloxacillin 
2g q4h
Notes
Consider Cloxacillin in intravenous drug users or in acute 
presentation
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Empirical therapy
Antimicrobials 
Likely Organisms
Prosthetic valve
Preferred
IV Vancomycin 
15-20mg/kg q12h
PLUS
IV Gentamicin 
3mg/kg q24h
PLUS
PO Rifampicin 
450mg q12h
PLUS OPTIONAL
IV Cefepime 
2g q8h
Alternative
Notes
For loading dose and monitoring of vancomycin refer to 
Appendix C.
Rifampicin is started 3-5 days later after vancomycin and 
gentamicin.
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Pathogen specific
Antimicrobials 
Likely Organisms
Streptococcus
 viridans
Streptococcus bovis
Highly penicillin-
susceptible:
MIC ≤ 0.12 µg/ml
Preferred
4 weeks regimen 
(Native)
6 weeks regimen 
(Prosthetic)
IV Benzylpenicillin 
3 million units q4h
OR
IV Ceftriaxone 
2g loading dose, 
1g q12h
Alternative
2 weeks regimen 
(Native)
IV Benzylpenicillin 
3 million units q4h
OR
IV Ceftriaxone 
2g loading dose, 
1g q12h
PLUS
IV Gentamicin 
3mg/kg q24h
Notes
The alternative 2-week regimen is not recommended 
for patients age > 65 years old, creatinine clearance
< 20ml/min, deafness and known cardiac or extra- cardiac 
abscesses and prosthetic valves.
Gentamicin is used for synergy, peak level need not 
exceed 4µg/ml and trough should be < 1µg/ml.
Benzylpenicillin:
1 million units = 600mg
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Pathogen specific
Antimicrobials 
Likely Organisms
Streptococcus
 viridans
Streptococcus bovis
Relatively resistant 
to penicillin:
0.12 µg/ml ≤ MIC < 
0.5 µg/ml
Group B, C and G 
streptococci
Preferred
IV Benzylpenicillin
4 million units q4h 
X 4 weeks
PLUS
IV Gentamicin 
3mg/kg q24h 
X 2 weeks
Alternative
IV Ceftriaxone 
2g loading dose, 
1g q12h  
X 4 weeks 
PLUS
IV Gentamicin 
3mg/kg q24h 
X 2 weeks
Notes
Duration of treatment in prosthetic valve endocarditis:
6 weeks.
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Pathogen specific
Antimicrobials 
Likely Organisms
Staphylococcus
 aureus
(Native valve)
Preferred
Methicillin sensitive
IV Cloxacillin 
2g q4h
X 4-6 weeks
Alternative
Methicillin resistant
IV Vancomycin 
15-20mg/kg q12h 
X 4-6 weeks
Notes
In uncomplicated right-sided endocarditis, duration of 
treatment can be shortened to 2-4 weeks. 
Uncomplicated right-sided endocarditis includes absence 
of: heart failure, extra-pulmonary metastatic infection 
such as osteomyelitis, aortic or mitral valve involvement, 
meningitis, MRSA infection, implanted prosthesis and 
AIDS. 
There is no evidence to routinely combine gentamicin 
with cloxacillin/vancomycin in native valve endocarditis. 
Gentamicin may help clear blood culture faster, does not 
affect mortality and have potential for harm.
For loading dose and monitoring of vancomycin refer to 
Appendix C.
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Pathogen specific
Antimicrobials 
Likely Organisms
Staphylococcus
 aureus
(Prosthetic valve)
Preferred
Methicillin sensitive
IV Cloxacillin 
2g q4h
X > 6 weeks
PLUS
PO Rifampicin 
450mg q12h 
X > 6 weeks
PLUS
IV Gentamicin 
1mg/kg q8h
X 2 weeks
Alternative
Methicillin resistant
IV Vancomycin 
15-20mg/kg q12h
X > 6 weeks
PLUS
PO Rifampicin 
450mg q12h
X > 6weeks
PLUS
IV Gentamicin 
1mg/kg q8h
X 2 weeks
Notes
To avoid the development of resistance, start rifampicin 
after 3-5 days of effective therapy and/or once 
bacteraemia has cleared.
For loading dose and monitoring of vancomycin refer to 
Appendix C.
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Pathogen specific
Antimicrobials 
Likely Organisms
Enterococcus spp
Enterococcus spp
(Vancomycin 
resistant)
HACEK
Haemophilus spp 
Aggregatibacter spp
Cardiobacterium
 hominis
Eikenella corrodens 
Kingella spp
Preferred
Ampicillin sensitive
IV Ampicillin 
2g q4h 
PLUS
IV Gentamicin 
1mg/kg q8h
IV Linezolid 
600mg q12h
X 6-8 weeks
IV Ceftriaxone 
2g loading dose, 
1g q12h
X 4 weeks
Alternative
Ampicillin resistant
IV Vancomycin 
15-20mg/kg q12h 
PLUS
IV Gentamicin 
1mg/kg q8h
IV Daptomycin 
10mg/kg q24
X 6-8 weeks
IV Ampicillin/
Sulbactam 3g q6h
X 4 weeks
Notes
Duration of treatment: 
Patient with native valve with symptoms < 3 months: 4 
weeks therapy for ampicillin and 2 weeks for gentamicin.
Patients with native valve with symptoms > 3 months: 6 
weeks therapy for ampicillin and gentamicin.
Prosthetic valves: 6 weeks.
If gentamicin is contraindicated or there is gentamicin 
resistance, consider combination of ampicillin or 
vancomycin with IV ceftriaxone 2g q12h.
6 weeks therapy for prosthetic valve endocarditis.
90
Bibliography:
1. Clinical Practice Guidelines for the Prevention, Diagnosis & 
 Management of Infective Endocarditis. National Heart Association 
 of Malaysia 2017
2. Eur Heart J. 2015: 36(44): 3075-3128
3. Circulation 2015; 132(15): 1435
4. Clin Infect Dis 2013; 56(9): 1261-8
5. Antimicrob Agents Chemother 2014; 58(3): 1556-64
91
Skin and soft tissue infections (SSTIs) are usually caused by bacterial entry through breaches in the skin. Its 
clinical severity depends on host factors such as age, diabetes mellitus and state of immunocompetence. 
Purulent SSTI, cellulitis, pyomyositis, and surgical site infections (SSI) can all result in severe illness, but the 
most severe end of the SSTI spectrum is composed of toxic shock syndrome, gas gangrene, and necrotising 
fasciitis.
Purulent SSTI
Purulent SSTIs (abscesses, furuncles, and carbuncles) are predominantly caused by S. aureus. Cutaneous 
abscesses are collections of pus within dermis and deeper tissues while furuncles and carbuncles are centered 
on hair follicles. Polymicrobial infections are possible depending on the site of infection. Infections that include 
anaerobes are more likely in the pelvic and lower extremity regions (particularly in those with peripheral vascular 
disease and/or diabetes). Enterobacteriaceae from the gut play a role in the polymicrobial milieu of pelvic 
abscesses.
SKIN AND SOFT TISSUE INFECTIONS
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Antimicrobials 
Likely Organisms
Staphylococcus
 aureus
Anaerobes
Enterobacteriacae
Preferred
IV Cloxacillin 
2g q4h
 
X 5-10 days
Alternative
IV Amoxycillin/
Clavulanate
1.2g q8h 
OR
IV Cefazolin 
1g q8h
PLUS
IV Metronidazole
500mg q8h
X 5-10 days
Notes
Duration of treatment depends on clinical response.
Incision and drainage needs to be done promptly.
Non-purulent SSTI: Cellulitis and Necrotising Fasciitis
Cellulitis is an acute diffuse infection of the epidermis, dermis and subcutaneous tissue. It is usually caused 
by ß-haemolytic Streptococci (most commonly Group A) or S. aureus. The most common presentation is a 
superficial spreading erythema usually associated with lymphangitis. Anaerobes and gram-negative organisms 
also play a role in non-purulent SSTIs of the lower extremities, particularly in patients with diabetes or peripheral 
vascular disease. 
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Necrotising fasciitis is an infection of the deeper tissues usually involving the extremities, the parapharyngeal 
space, the abdominal wall or the perineum (Fournier’s gangrene). In the early stages, cellulitis may be difficult to 
differentiate from necrotising fasciitis. Presence of severe pain, bullae, crepitus, progressive spread of infection 
despite appropriate antibiotics, renal failure and systemic deterioration are all suggestive of necrotising fasciitis. 
Although supportive management of organ failure and antimicrobials play a major role, surgical debridement 
often extensive and repeated is essential. Tissue cultures taken at the time of debridement may help to identify 
the organism.
There is anatomical variation in predominant pathogens. In the neck region, oral flora including anaerobes, tend 
to be the more likely organism as in Ludwig’s angina. Infections in the pelvic region more commonly result 
from Enterobacteriaceae from the genitourinary or gastrointestinal tracts. There are 3 types of necrotising 
fasciitis. Type 1 is polymicrobial and is usually seen in patients with peripheral vascular disease, alcoholics, 
diabetes, chronic kidney disease and after surgical procedures. Type 2 is caused by ß-haemolytic streptococcus. 
It commonly occurs in patients with no medical illnesses, predisposed by blunt trauma, varicella infection, 
intravenous drug abuse and surgical procedures. Type 3 infection is clostridial myonecrosis, also known as gas 
gangrene. It often occurs in penetrating wounds or crush injuries associated with local devascularisation and 
can rapidly progress to death.
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Cellulitis
Necrotising fasciitis
Antimicrobials 
Likely Organisms
ß-haemolytic 
 Streptococci
Staphylococcus
 aureus
Head and Neck
Streptococcus spp 
Anaerobes 
Peptostreptococci
Fusobacterium spp
Prevotella spp
Bacteroides spp
(usually not 
Bacteroides fragilis)
Preferred
IV Cloxacillin 
2g q4h 
X 5-10 days
IV Amoxycillin/
Clavulanate
1.2g q8h
OR
IV Ampicillin/Sulbactam 
3g q6h
Alternative
IV Amoxycillin/
Clavulanate
1.2g q8h 
X 5-10 days
Notes
If streptococci is cultured consider IV benzylpenicillin
4 million units q6h.
IV benzylpenicillin: 1 million units = 600mg
Duration of treatment depends on clinical response.
Includes deep neck space infections e.g. submandibular 
(Ludwig’s angina), parapharyngeal, retropharyngeal and 
peritonsillar space infection.
Most of these infections have an odontogenic source.
Gram-negative rods to be considered in the 
immunocompromised host.
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Necrotising fasciitis
Antimicrobials 
Likely Organisms
Abdominal/
Perineum
Bacteroides spp
Clostridium spp
Peptostreptococci
Enterobacteriaceae
Pseudomonas 
 aeruginosa
Preferred
IV Ampicillin/
Sulbactam
3g q6h
OR
IV Ceftriaxone
2g loading dose, 
1g q12h 
PLUS
IV Metronidazole
500mg q8h
PLUS
IV Clindamycin
900mg q8h
Alternative
IV Piperacillin/ 
Tazobactam 
4.5g q6h
OR
IV Cefepime 
2g q8h
PLUS
IV Metronidazole
500mg q8h
OR
IV Imipenem 
1g q8h
PLUS
IV Clindamycin 
900mg q8h
Notes
Continue treatment until surgical debridement is no 
longer needed and patient has clinically improved.
If ESBL organisms are suspected use imipenem.
If Clostridium spp or ß-haemolytic streptococci is 
confirmed, deescalate to IV benzylpenicillin 2 million 
units q4h but continue clindamycin.
If IV Clindamycin is not available, PO Clindamycin 600mg 
q6h may be used.
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Necrotising fasciitis
Antimicrobials 
Likely Organisms
Chest and 
extremities
ß-haemolytic 
streptococci
Staphylococcus 
 aureus
Bacteroides spp 
Clostridium spp 
Peptostreptococci
Enterobacteriaceae
Preferred
IV Ampicillin/ 
Sulbactam
3g q6h
OR
IV Ceftriaxone 
2g loading dose, 
1g q12h 
PLUS
IV Metronidazole
500mg q8h
PLUS
IV Clindamycin
900mg q8h
Alternative
IV Piperacillin/ 
Tazobactam 
4.5g q6h
OR
IV Cefepime 
2g q8h
PLUS
IV Metronidazole
500mg q8h
OR
IV Imipenem 
1g q8h
PLUS
IV Clindamycin 
900mg q8h
Notes
If streptococcal toxic shock syndrome is suspected 
consider IVIg.
If ESBL organisms are suspected use imipenem.
Vancomycin / Linezolid needs to be considered in cases 
where MRSA are likely.
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Necrotising fasciitis
Antimicrobials 
Likely Organisms
Aeromonas
 hydrophila
Vibrio vulnificus
Preferred
IV Ceftriaxone 
2g loading dose, 
1g q12h
PLUS
PO Doxycycline
100mg q12h
X 7-10 days
Alternative
IV Ciprofloxacin 
400mg q8h
X 7-10 days
Notes
Aeromonas spp and Vibrio spp need to be 
considered in water-related injuries. At risk are the 
immunocompromised, diabetics and those with liver 
cirrhosis.
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Surgical Site infection
Most surgical site infections have no clinical manifestation for the first 5 days after the operation. The most 
important intervention is to open the wound, drain the infected material and continue to dress the wound daily. 
Empiric antimicrobial is usually guided by the site of infection.
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The approach to the patient with suspected acute central nervous system infection is early recognition, 
performance of rapid diagnostic tests, prompt antimicrobial therapy and adjunctive therapy whenever 
appropriate.
Acute bacterial meningitis should not be ruled out solely on the absence of classical signs and symptoms. In 
patients with suspected bacterial meningitis, it is strongly recommended to perform lumbar puncture to obtain 
CSF for analysis and blood cultures. The choice of empirical antibiotic is influenced by the patient’s age, immune 
status and predisposing conditions. The antibiotic should have bactericidal action with high concentration in the 
CSF as the immune activity in the CSF is poor.
Corticosteroids have been shown to significantly reduce hearing loss and neurologic sequelae but did not 
reduce overall mortality. It is recommended to administer dexamethasone before or with the first dose of 
empirical antibiotic in all adults with acute bacterial meningitis. Discontinue dexamethasone if the causative 
organism is not Haemophilus influenzae, Streptococcus pneumoniae or Mycobacterium tuberculosis.
Viral encephalitis has a similar presentation as bacterial meningitis. However encephalitis has more prominent 
neurological symptoms of altered sensorium, focal signs and seizures. Until CSF analysis suggests otherwise 
or a definitive organism is identified, empirical therapy usually includes acyclovir even though it is only specific 
to herpes virus (herpes simplex and varicella zoster) infection.
CENTRAL NERVOUS SYSTEM INFECTION
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Meningitis associated with invasive neurological procedures or head trauma is classified as healthcare-
associated ventriculitis and meningitis, with resistant Gram-negative bacilli and staphylococci being the 
more likely causative organisms. Intrathecal or intraventricular administration of antibiotics (aminoglycosides, 
polymyxins, vancomycin) is not practised routinely. It may be used with parenteral antibiotics in infections due 
to multi-drug resistant organisms or infections refractory to appropriate parenteral therapy. Determining the 
correct dosing regimen to achieve CSF antimicrobial concentrations of 10-20 times the MIC of the causative 
microorganism is challenging. CSF concentrations are highly variable depending on the volume of distribution, 
ventricular size, and CSF clearance as a result of CSF drainage.
Empirical therapy in community-acquired meningo-encephalitis
Antimicrobials 
Likely Organisms
Streptococcus
 pneumoniae
Neisseria meningitidis 
Haemophilus
 influenzae
Aerobic Gram-negative 
bacilli
(more common 
in age > 50, 
immunocompromised)
Preferred
IV Ceftriaxone 
2g loading dose, 
2g q12h 
OR
IV Cefotaxime 
2g q6h
Alternative
Notes
Add IV vancomycin if prevalence of cephalosporin-
resistant S. pneumoniae is > 2%. 
Administer IV dexamethasone 10mg q6h X 4 days, 
20 minutes before or with the first dose of antibiotic. 
Omit if antibiotics have been started. Discontinue 
if the causative organism is not H. influenzae or 
S. pneumoniae.
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Empirical therapy in community-acquired meningo-encephalitis (cont’d)
Antimicrobials 
Likely Organisms
Listeria
 monocytogenes
(uncommon in 
Malaysia)
Herpes simplex virus
Varicella zoster virus 
Enteroviruses
Japanese B
 encephalitis virus 
Adenovirus
Cytomegalovirus 
Epstein-Barr Virus
Mycobacterium
 tuberculosis
Preferred
PLUS OPTIONAL
IV Acyclovir 
10mg/kg q8h
X 14 days 
Refer to chapter on 
Tuberculosis
Alternative
Notes
Treat Listeria meningitis with IV ampicillin 2g q4h if 
CSF Gram stain reveals Gram-positive rods or when 
confirmed.
Duration of treatment:
•	 N. meningitidis X 7days
•	 H. influenzae X 7-10 days
•	 S. pneumoniae X 10-14 days
•	 Aerobic	Gram-negative	bacilli	X	21	days
•	 L. monocytogenes X 21 days (longer if 
 immunocompromised)
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Empirical therapy in healthcare-associated ventriculitis and meningitis
Antimicrobials 
Likely Organisms
Staphylococcus aureus
Coagulase-negative
 staphylococcus
Propionibacterium
 acnes
Aerobic Gram-negative
 bacilli
 Pseudomonas
  aeruginosa
 Acinetobacter spp
Candida spp
Preferred
IV Cloxacillin 
2g q4h
PLUS
IV Cefepime 
2g q8h
Alternative
IV Vancomycin 
15 - 20mg/kg q12h
PLUS
IV Meropenem 
2g q8h
PLUS OPTIONAL
IV Polymyxin E 
9 million units loading 
dose and 12 hours 
later 4.5 million units 
q12h
Notes
Duration of therapy:
•	 CoNS	or	P. acnes
  X 10 days (minimal CSF abnormalities)
  X 10-14 days (significant CSF abnormalities and 
  systemic features)
•	 S. aureus or Gram-negative bacilli X 10-14 days
If CSF cultures are repeatedly positive despite on 
appropriate antimicrobial, continue for 10-14 days after 
last positive culture.
Remove infected shunts. A new shunt can be placed 
after repeat CSF cultures are negative but the timing 
of placement varies between pathogens:
•	 CoNS	or	P. acnes (minimal CSF abnormalities) 
  - 3 days after removal
•	 CoNS	or	P. acnes (significant CSF abnormalities) 
  - 7-10 days from negative CSF culture
•	 S. aureus or Gram-negative bacilli
  - 10 days from negative CSF culture
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Brain abscesses are uncommon but can occur in immunocompetent hosts secondary to contiguous foci 
of infection (dental, middle ear or sinus) or haematogenous spread from an extracranial site of infection 
(endocarditis, lung abscess) or in cyanotic heart disease, immunocompromised hosts, and after neurosurgical 
procedures. It is usually difficult to diagnose brain abscess on clinical grounds alone and neuroimaging is 
necessary. Bacterial abscess in the brain is preceded by infarction and cerebritis. Antibiotic therapy during the 
early stage may prevent the progress from cerebritis to abscess. 
Empiric antimicrobial therapy should be based on the mechanism of infection, host immune status and the 
ability of the antimicrobial to penetrate the abscess. Attempts should be made to obtain microbiological culture 
to allow directed therapy especially in the immunocompromised host. Surgical drainage may be necessary; 
especially in lesions larger than 2.5 cm. Frequent repeat neuroimaging is indicated to monitor treatment 
response. 
Dexamethasone use is controversial but may be administered when a significant mass effect is seen on 
imaging and the patient’s mental status is depressed. It should be discontinued once the mass effect and 
neurological status has improved. Steroids can retard the encapsulation process, increase necrosis, reduce 
antibiotic penetration into the abscess, increase the risk of ventricular rupture, and produce a rebound effect 
when discontinued.
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Brain abscess
Immunocompetent host: contiguous or haematogenous spread, penetrating trauma or post neurosurgery
Antimicrobials 
Likely Organisms
Aerobic and anaerobic
 streptococci
Bacteroides
Enterobacteriaceae
Haemophilus influenzae
Staphylococcus aureus
Aerobic Gram-negative 
 bacilli
  Pseudomonas 
   aeruginosa
 Acinetobacter spp
Preferred
IV Ceftriaxone 
2g loading dose, 2g q12h
OR
IV Cefotaxime 
2g q6h
PLUS
IV Metronidazole 
1g loading dose, 
500mg q8h 
PLUS OPTIONAL
IV Cloxacillin 
2g q4h
Alternative
IV Cefepime 
2g q8h
PLUS
IV Metronidazole 
1g loading dose, 
500mg q8h
OR
IV Meropenem 
2g q8h
PLUS OPTIONAL
IV Vancomycin 
15-20mg/kg q12h
Notes
Consider alternative antimicrobial therapy to cover 
nosocomial aerobic Gram-negative bacilli. 
Metronidazole is added to cover penicillin-resistant 
anaerobic Gram-negative bacilli (Bacteroides) in abscess 
of dental, middle ear or sinus origin and in penetrating 
injury of paranasal sinus involvement. 
Empiric antibiotic to cover for S. aureus is indicated 
in abscess secondary to haematogenous spread, 
penetrating injury, post neurosurgery and in those at 
high risk for S. aureus sinusitis (recent endoscopic sinus 
surgery, chronic sinusitis, recent nasal packing). 
Consider anti-MRSA cover in patients with risk for 
MRSA infection.
For loading dose and monitoring of vancomycin refer to 
Appendix C.
For empirical treatment of brain abscess associated with 
endocarditis, refer to chapter on Infective Endocarditis.
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Brain abscess (cont’d)
Immunocompetent host: contiguous or haematogenous spread, penetrating trauma or post neurosurgery
Immunocompromised host: solid organ or bone marrow transplant recipients
Antimicrobials 
Likely Organisms
Aspergillus spp
Candida spp
Mucorales
Cryptococcus neoformans
Nocardia
Listeria monocytogenes
Mycobacterium tuberculosis
Preferred
Alternative antimicrobials 
as per immunocompetent 
host
PLUS
IV Voriconazole
D1 6mg/kg q12h 
followed by 4mg/kg q12h
OR
IV Liposomal 
Amphotericin B 
5mg/kg q24h
Alternative
Notes
Duration of therapy:
•	 cerebritis	or	post	drainage	X	4-6	weeks
•	 encapsulated	abscess	with	tissue	necrosis,	
 multiloculated abscess, abscess in vital locations 
 (e.g. brain stem) X minimum 6 weeks 
•	 immunocompromised	X	minimum	6	weeks
Aspergillus brain abscess usually occurs in the setting 
of disseminated aspergillosis. Consider combination 
antifungal in Aspergillus CNS infection.
Suspect nocardia brain abscess in presence of lung 
abscess.
Suspect listeria brain abscess in presence of prodrome 
of meningoencephalitis and brain stem location of 
abscess.
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Brain abscess (cont’d)
Immunocompromised host: HIV infected
Antimicrobials 
Likely Organisms
Toxoplasma gondii
Cryptococcus neoformans
Mycobacterium tuberculosis
Listeria monocytogenes
Preferred
Alternative antimicrobials 
as per immunocompetent 
host
PLUS
PO Pyrimethamine 
D1 200mg followed by 
50mg q24h (BW < 60kg)
75mg q24h (BW > 60kg)
PLUS
PO Sulfadiazine 
1g q6h (BW < 60kg) 
1.5g q6h (BW > 60kg)
 
PLUS
PO Folinic acid 
10 -25mg q24h
Alternative
Notes
Suspect toxoplasma brain abscess in advanced AIDS, 
positive serum toxoplasma IgG, lack of prophylaxis and 
multiple ring-enhancing basal ganglia lesions.
In a single enhancing brain lesion and with an 
undetectable anti-toxoplasma IgG, brain biopsy is 
recommended to rule out CNS lymphoma.
Suspect listeria brain abscess in presence of prodrome 
of meningoencephalitis and brain stem location of 
abscess.
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Brain abscess (cont’d)
Pathogen specific
Antimicrobials 
Likely Organisms
Listeria monocytogenes
Candida spp
Toxoplasma gondii
Preferred
IV Ampicillin 2g q4h
IV Liposomal 
Amphotericin B 
5mg/kg q24h
Induction therapy
PO Pyrimethamine 
D1 200mg followed by 
50mg q24h (BW < 60kg)
75mg q24h (BW > 60 kg)
PLUS
IV/PO Clindamycin 
600mg qid
PLUS
PO Folinic acid 
10-25mg q24h
X 6 weeks (minimum)
Alternative
IV Trimethoprim/
Sulfamethoxazole 
5mg/kg q6h (TMP 
component)
IV Fluconazole 
800mg q24h
Notes
Duration of therapy:
- minimum 6 weeks 
Duration of therapy:
- not definitively determined
Duration of therapy
•	 induction	therapy	
 X minimum 6 weeks (longer duration if clinical or
 radiologic disease is extensive)
•	 maintenance	therapy	
 PO pyrimethamine 25-50mg q24h, 
 PO clindamycin 600 mg q8h and PO folinic acid
 10-25mg q24h
 until asymptomatic of signs and symptoms of CNS 
 toxoplasmosis and CD4 count > 200 cells/mm3 for
 > 6 months in response to anti-retroviral therapy.
•	 If	pyrimethamine	is	unavailable,	consider	Fansidar.
 For alternative regimen, refer ID.
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Brain abscess (cont’d)
Pathogen specific
Antimicrobials 
Likely Organisms
Cryptococcus neoformans
Aspergillus spp
Preferred
Induction therapy
IV Liposomal 
Amphotericin B 
3-4mg/kg q24h 
PLUS
PO Flucytosine 
25mg/kg q6h
X 2 weeks
IV Voriconazole
D1 6mg/kg q12h 
followed by 4mg/kg q12h
Alternative
IV Amphotericin B
0.7-1mg/kg q24h
OR
IV Amphotericin 
lipid-complex
5mg/kg q24h
PLUS
PO Flucytosine 
25mg/kg q6h
X 2 weeks
IV Liposomal 
Amphotericin B 
5mg/kg q24h
Notes
After induction therapy, continue with
•	 consolidation	therapy,	IV	fluconazole	400mg	q24h	X
 minimum 8 weeks
•	 maintenance	therapy,	PO	fluconazole	200mg	X	
 minimum 1 year 
Adjust flucytosine dose in patients with renal 
dysfunction.
For alternative regimen, refer ID.
After clinical improvement following parenteral 
antifungal, continue therapy with PO voriconazole 
200mg q12h.
Duration of therapy:
- until infection is resolved. 
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Brain abscess (cont’d)
Pathogen specific
Antimicrobials 
Likely Organisms
Nocardia spp
Mucorales
Mycobacterium tuberculosis
Preferred
IV Trimethoprim/
Sulfamethoxazole
5mg/kg q6h (TMP 
component)
IV Liposomal 
Amphotericin B 
5mg/kg q24h 
Refer to chapter on 
Tuberculosis.
Alternative
Notes
Species identification of Nocardia is important, as 
antimicrobial susceptibility varies.
Combination therapy with carbapenems, amikacin, 3rd 
generation cephalosporins may be used and continued 
until clinical improvement occurs. 
Therapy may continue with oral minocycline, amoxicillin/
clavulanate and linezolid after an induction course of 
parenteral therapy. 
Duration of therapy: 
- minimum 12 months
Duration of therapy:
- minimum 6-8 weeks
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Melioidosis is a potentially fatal disease caused by Burkholderia pseudomallei. There is no reliable pathognomonic 
feature and can present as bacteraemia with no obvious focal infection or as septic shock with multi-organ 
failure. Common sites of infection include the lung (50%), joints, spleen, liver, skin and prostate. In bacteraemic 
cases, CT or ultrasound of the abdomen and pelvis is required to detect any abscesses. 
Predisposing host factors to melioidosis include diabetes mellitus, renal failure, chronic lung disease, alcoholism, 
steroid use, malignancy and HIV infection. Other risk factors include occupational and recreational exposure to 
surface water and mud e.g. rice farmers, construction site workers and adventure travellers. Melioidosis can 
also occur sporadically during the rainy seasons or floods.
Antibiotic therapy consists of 2 phases, an initial intensive treatment phase for at least 2 weeks followed by 
an eradication phase for 12-20 weeks to prevent relapse and recurrence. Prolonged IV therapy is necessary 
for complicated pneumonia, deep-seated infection including prostatic abscesses, central nervous system 
involvement, osteomyelitis and septic arthritis. The actual eradication phase is guided by the site of infection 
and the clinical response to therapy. Deep-seated abscesses may need to be drained. Infected joints also need 
surgical intervention.
MELIOIDOSIS
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PLUS OPTIONAL
IV Trimethoprim/Sulfamethoxazole 5mg/kg 
(TMP component) q12h (in deep seated focal 
infections, CNS, joints, bones, prostate)
PO Trimethoprim/Sulfamethoxazole
>60kg 320:1600mg q12h
40-60kg 240:1200mg q12h
<40kg 160:800mg q12h
OR
PO Amoxycillin/Clavulanate 500/125mg q8h
Phase 1: Treatment
Phase 2: Eradication
Antimicrobials 
Likely Organisms
Burkholderia
 pseudomallei
Preferred
IV Meropenem 
1g q8h
(2g q8h for CNS infection)
OR
IV Imipenem
1g q8h
Alternative
IV Ceftazidime 
2g q6h
Notes
Carbapenem is preferred in severe sepsis as the benefits 
include:
•	 higher	rate	of	bacterial	killing	in	vitro	due	to	enhanced	
 cell wall penetration
•	 better	post-antibiotic	effect	
•	 decreased	endotoxin	release
Evidence for the use of G-CSF is weak. It may be considered 
in septic shock patients admitted within 72 hours to ICU. 
IV G-CSF 300µg daily x 10 days
(contraindications: acute coronary event, total WCC > 
50,000 x106/L)
Add PO Folic Acid 5mg q24h
Add PO Folic Acid 5mg q24h 
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Duration of therapy for Burkholderia pseudomallei infections
Clinical focus
Skin abscess
Bacteraemia with no focus
Pneumonia
Prostatic abscess, septic arthritis, 
organ or deep-seated tissue collection
Osteomyelitis
Central nervous system infection
Mycotic aneurysms
Minimum intensive intravenous phase
(weeks)
2
2
2 to 4
4
6
8
8
Eradication oral phase (weeks)
12
12
12
12
24
24
Maybe lifelong
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Leptospirosis is a zoonotic infection caused by pathogenic spirochetes of the genus Leptospira. It is commonly 
associated with rodents in the settings of poor sanitation, high-risk occupations (sewerage workers, livestock 
handlers), flooding and recreational activities conducted in contaminated water or soil. The clinical manifestations 
of leptospirosis vary from mild febrile illness to the icteric-haemorrhagic form with severe kidney and liver 
involvement, myocarditis and pulmonary haemorrhage. 
Presumptive diagnosis is made with a positive rapid screening test such as IgM ELISA. However, its specificity 
is affected by previous exposure (significant in endemic areas and may remain detectable for several years) and 
other diseases. Diagnosis is confirmed with a fourfold or greater rise in antibody titres or seroconversion in the 
microscopic agglutination test (MAT) on paired samples obtained 2 weeks apart. Hence treatment should be 
initiated even when the initial test is negative if the clinical picture is consistent. Blood for PCR testing can be 
done. Blood cultures are not routinely done as it requires specialised media and can only be recovered early in 
the illness.
LEPTOSPIROSIS
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Antimicrobials 
Likely Organisms
Leptospira spp
Preferred
IV Benzylpenicillin 
2 million units q6h 
X 7 days
Alternative
IV Ceftriaxone 2g 
loading dose, 1g q12h
X 7 days
Notes
In less severe infection:
PO Azithromycin 500 mg q24h x 3 days 
OR
PO Doxycyline 100mg q12h x 5-7 days
OR 
PO Amoxicillin 500mg q8h x 7 days
Jarisch-Herxheimer reaction can occur post ß-lactam 
therapy
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Patients diagnosed or suspected with severe malaria should be started on parenteral anti-malarial therapy 
immediately. Severe malaria with multiorgan dysfunction is usually due to Plasmodium falciparum. Occasionally 
severe malaria may be due to P. knowlesi, P. vivax or a mix coinfection with P. falciparum. P. knowlesi may be 
misdiagnosed as P. malariae on blood film. Patients with severe malaria are at risk of concurrent bacterial 
infection.
Microscopic examination of thick and thin blood films remain the standard for detection, species identification 
and quantification. Rapid diagnostic kits can detect parasite antigens with high sensitivity but must be 
confirmed with microscopy. The PCR method is useful for confirmation and species determination in special 
circumstances (clinical malaria with negative blood films or microscopic diagnosis of P. malariae).
SEVERE MALARIA
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Antimicrobials 
Likely Organisms
Plasmodium
 falciparum
Plasmodium knowlesi
Plasmodium vivax
Preferred
IV Artesunate 2.4mg/kg 
at 0 hrs, 12 hrs and 
24 hrs then q24h 
X 7 days
PLUS
PO Doxycyline 
200mg q24h
X 7 days
Alternative
IV Quinine 
Dihydrochloride 
20mg/kg in 250mls 
D/5% over 4 hours 
and then
10mg/kg q8h 
PLUS
PO Doxycyline 
200mg q24h
X 7 days
Notes
If artesunate is not readily available, start quinine first 
to avoid delay. Blood sugars and QT intervals need to 
be monitored regularly while on quinine. 
Switch to oral Artemisinin Combination Therapy (ACT) if 
patient is able to tolerate orally and after 24 hours of IV 
artesunate. Oral Riamet (lumefantrine and artemether) 
is available in Malaysia. Complete the 6 doses. 
Substitute doxycyline with PO clindamycin 450mg q8h 
in pregnancy.
If there is no decrement in parasite counts after 72 
hours, suspect reduce susceptibility to artemisinin.
In P. vivax infection, add PO primaquine 0.5mg/kg 
(max 30mg) q24h for 14 days to prevent relapse by 
eliminating hypnozoites in the liver.
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Invasive candidiasis (IC) is increasingly common in ICU patients and results in high mortality if treatment is 
delayed or inappropriate. IC consists of candidaemia with or without metastatic complications; or deep-seated 
candidiasis (often blood culture negative e.g. intra-abdominal or hepatosplenic candidiasis). Although Candida 
albicans is the most common organism, there is a growing proportion of non-albican species, that is associated 
with fluconazole resistance. Other invasive fungal infections e.g. aspergillosis, mucormycosis are rare except in 
neutropenic or transplant recipients. 
Colonisation with candida in the oropharynx, respiratory and urinary tract is common in ICU patients and is not 
an indication for treatment. Broad-spectrum antibiotic therapy increases the incidence of colonisation. Overall 
the risk of invasive infection increases with the number and extent of colonised sites. Candida pneumonia is 
very rare and only occurs in severely immunocompromised patients following haematogenous spread.
Blood culture remains the gold standard for diagnosis of IC. However, it is negative in 50% of IC and time 
to positivity is long (up to 72 hours and longer for species identification) contributing to poor outcomes from 
treatment delays. Nonculture-based diagnostic tests such as serological (mannan/antimannan, ß-D-glucan) and 
molecular (candida-specific PCR) techniques may be useful adjuncts to early diagnosis but are not routinely 
available here. 
INVASIVE CANDIDIASIS IN THE NON-NEUTROPENIC PATIENT
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Assessing risks has become the cornerstone of empiric treatment of candida infections in the ICU setting. 
Patients at risk for IC are:
	 •	 High	severity	of	illness
	 •	 Long	term	ICU	stay
	 •	 Gastrointestinal	surgery	with	anastomotic	leakages	or	recurrent	gastro-duodenal	perforations
	 •	 Acute	necrotising	pancreatitis
	 •	 Immunocompromised/immunosuppressive	therapy	e.g.	steroid	use	or	chemotherapy
	 •	 Solid	organ	transplant
	 •	 Haematologic	or	solid	organ	malignancies
	 •	 Candida	colonisation	at	multiple	non-sterile	sites	e.g.	colonisation	index	>	0.5	(no.	of	sites	colonised/no.	
  of sites cultured) 
	 •	 Use	of	broad-spectrum	antibiotics
	 •	 Presence	of	central	venous	catheters
	 •	 Parenteral	nutrition
	 •	 Haemodialysis
However, there is no single factor that determines infection risk but rather a combination that may suggests a 
role	in	the	initiation	of	anti-fungal	therapy.	Scoring	systems	and	predictive	rules	that	combine	risk	factors	and	
microbiological tools lack sensitivity although have high negative predictive value. 
Anti-fungals can be used as prophylactic, empiric, pre-emptive or definitive therapy. Prophylaxis therapy is 
initiated	in	asymptomatic	patients	with	high	risks	for	fungal	infection.	In	ICUs	with	IC	rates	of	>	5%,	experts	
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suggest	 the	 use	 of	 prophylactic	 treatment	 for	 patients	with	 recurrent	 GI	 surgery	 and	 leaks	 or	 undergoing	
transplantation.
Empirical therapy should be started in a patient with unexplained sepsis with risk factors for IC while
pre-emptive therapy is for similar patients with radiological or serological evidence for IC. The agent of choice 
depends on the suspected pathogen, site of infection, severity of illness and local susceptibility patterns. If the 
response is positive, continue therapy for 2 weeks. 
In cases of persistent fever or candidaemia during appropriate treatment, rule out ongoing foci of infection e.g. 
endocarditis, infected intravascular catheters or abscesses within solid organs.
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Empirical therapy
Antimicrobials Likely Organisms
Candida spp
Without risk factors for 
resistant Candida spp
OR
Haemodynamically stable 
with risk factors for 
resistant Candida spp
IV Fluconazole 
D1 800mg 
followed by 400mg q24h
With risk factors for 
resistant Candida spp
AND 
haemodynamically
unstable
IV Anidulafungin
D1 200mg 
followed by 100mg q24h
OR
IV Caspofungin
D1 70mg 
followed by 50mg q24h
OR
IV Micafungin 100mg q24h
OR 
IV	Lipid	formulation	
Amphotericin B 
3-5mg/kg q24h 
OR
IV Amphotericin B 
0.6-1mg/kg q24h
Notes
Risks factors for azole resistant candida:
• previous azole exposure within last 3 months
• previous abdominal surgery
• solid organ tumours
• haemopoietic transplant
• chemotherapy with extensive mucositis
In haemodynamically stable patients with risk 
factors, a balance must be struck between the 
overuse of echinocandins and inappropriate 
therapy. Monitor closely and change to an 
echinocandin if no response.
There is no documented superiority of one 
echinocandin over another. 
Lipid	 formulation	 Amphotericin	 B	 (AmB)	 is	
preferred for better safety profile.
AmB is the treatment of choice in pregnant 
women.
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Pathogen specific
Antimicrobials Likely Organisms
Candida albicans
Preferred
IV Fluconazole 
D1 800mg 
followed by 400mg q24h
Alternative
IV Anidulafungin 
D1 200mg 
followed by 100mg q24h
OR
IV Caspofungin 
D1 70mg 
followed by 50mg q24h
OR
IV Micafungin 100mg q24h
OR
IV	Lipid	formulation	
Amphotericin B 
3-5mg/kg q24h
OR
IV Amphotericin B 
0.6-1mg/kg q24h
Notes
Repeat cultures every 48 hours till negative. 
Duration of treatment without metastatic 
complication is 14 days from first negative blood 
culture with resolution of signs and symptoms of 
infection.
If there are metastatic complications, the duration 
of treatment should be based on the site, clinical 
improvement and resolution of lesions on imaging.
Echinocandins do not achieve therapeutic 
concentrations	in	the	CNS,	eye	and	urine.
Ophthalmic examination is recommended for 
all patients with candidaemia within 1 week of 
diagnosis. Risk of endophthalmitis is up to 25%.
Central venous catheters must be removed as 
soon as possible in candidaemia.
AmB is the treatment of choice in pregnant 
women.
Flucytosine can be added for combination 
with AmB for more refractory infections e.g. 
endophthalmitis, meningitis and endocarditis
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Pathogen specific
Antimicrobials Likely Organisms
Candida
 parapsilosis
Candida tropicalis
Candida
 lusitaniae
Candida glabrata
Candida krusei
Preferred
IV Fluconazole 
D1 800mg 
followed by 400mg q24h
IV Anidulafungin
D1 200mg 
followed by 100mg q24h
OR
IV Caspofungin
D1 70mg 
followed by 50mg q24h
OR
IV Micafungin 100mg q24h
Alternative
IV	Lipid	formulation	
Amphotericin B 
3-5mg/kg q24h
OR
IV Amphotericin B 
0.6-1mg/kg q24h
IV	Lipid	formulation	
Amphotericin B 
5mg/kg q24h
OR
IV Amphotericin B 
0.6-1mg/kg q24h
Notes
C. lusitaniae may be resistant to amphotericin B.
In C. glabrata that is fluconazole-susceptible, 
deescalate to higher dose fluconazole 800mg 
q24h.
Consider stepdown therapy to oral voriconazole in 
patients with C. krusei that are stable.
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APPENDIX A
DOSAGE ADJUSTMENT FOR RENAL IMPAIRMENT
Below is the formula used to calculate the creatinine clearance (CrCl):
Males: CrCl (mls/min) =     (140 – Age) x IBW* Females: CrCl (mls/min) = (140 – Age) x IBW*
 0.8 x Sr. creat (μmol/L)  Sr. creat (μmol/L)
*In obese patients use adjusted body weight. If BMI < 18.5 kg/m2 use actual BW. Refer Appendix E for BW calculations.
§ Alternative calculation for CrCl is the CKD-EPI (Chronic Kidney Disease Epidemiology Collaborative) equation with the removal of body surface area nomalisation.
Adjusted Maintenance Dose for Renal Impairment and Dialysis
Loading dose (LD) is required prior to Maintenance Dose (MD)
Drug / Normal Dose
Amikacin
Acyclovir
MD : 10mg/kg/dose q8h
Ampicillin
LD : 2g
MD : 2g q4h - q6h*
*Higher dose range for 
endocarditis and meningitis
Ampicillin/sulbactam
LD : 3g
MD : 3g q6h
*Refer table for dosing in MRO 
Acinetobacter baumanii infecion
CrCl
30-50 ml/min
10mg/kg/dose q12h
2g q6h - q8h
3g q8h
CrCl
10-30 ml/min
10mg/kg/dose q24h
2g q8h - q12h
3g q12h
CrCl
< 10 ml/min
5mg/kg/dose q24h
2g q12h - q24h
3g q24h
Renal Replacement Therapy
HD: 5mg/kg/dose q24h†
CVVH: 10mg/kg/dose q24h
CVVHD/CVVHDF: 10mg/kg q12h 
HD: 2g q12h†
CVVH: 2g q8h - q12h
CVVHD: 2g q8h
CVVHDF: 2g q6h - q8h
HD: 3g q24h†
CVVH: 3g q12hr
CVVHD: 3g q8hr
CVVHDF: 3g q6h
Refer Appendix C
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Adjusted Maintenance Dose for Renal Impairment and Dialysis
Loading dose (LD) is required prior to Maintenance Dose (MD)
Drug / Normal Dose
Amoxicillin/clavulanate
LD : 1.2g 
MD : 1.2g q8h
Benzylpenicillin
LD : 4MU
MD : 2-4MU q4h - q6h
Cefepime
LD : 2g
MD : 2g q12h - q8h*
* Higher dose for meningitis, VAP 
and febrile neutropenia
Ceftazidime
LD : 2g
MD : 2g q8h - q6h*
* Higher dose range for 
Melioidosis
Cefuroxime
LD : 1.5g
MD : 1.5g q8h
CrCl
< 10 ml/min
1.2g q24h
1-2MU 
q4h - q6h
1g q24h
1g q24h
1.5g q24h
Renal Replacement Therapy
HD: 1.2g q24hr + 600mg AD
CVVH: 1.2g q12hr 
HD: 1-2MU q4h - q6h†
CVVH: 2MU q6h
CVVHD: 2MU q4h
CVVHDF: 4MU q4h
HD: 1g 24h + 1g AD
CVVH: 2g q12h
CVVHD/CVVHDF: 2g q12h or 2g q8h*
HD: 2g q24hr + 1g AD 
CVVH: 2g q12h
CVVHD/CVVHDF: 2g q12h or 2g q8h
HD: 1.5g q24h†
CVVH: 1.5g q8h - q12h
1.5-3MU q4h - q6h
CrCl
30-50 ml/min
1.2g q8h
2g q12h
2g q12h
Unchanged
CrCl
10-30 ml/min
1.2g q12h
2g q24h
2g q24h
1.5g q12h
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200mg - 400mg q24h
Adjusted Maintenance Dose for Renal Impairment and Dialysis
Loading dose (LD) is required prior to Maintenance Dose (MD)
Drug / Normal Dose
Ciprofloxacin
LD : 400mg
MD : 400mg q12h - q8h*
* Higher dose for P. aeruginosa 
infection
Daptomycin
MD : 10 mg/kg q24h
Doripenem
LD : 500mg 
MD : 500mg q8h
Ertapenem
LD  : 1g
MD : 1g q24h
Ethambutol
15 - 20mg/kg q24h
Fluconazole
Day 1: 800mg
MD : 400mg - 800mg q24h*
*Higher dose for certain fungal 
infections
CrCl
< 10 ml/min
400mg q24h
10mg/kg q48h
No data
500mg q24h
15-20mg/kg q48h
Renal Replacement Therapy
HD: 400mg q24h†
CVVH: 200mg-400mg q12h
CVVHD/CVVHDF: 400mg q12h
HD/CVVH/CVVHD/CVVHDF: 10mg/kg q48h
HD: 500mg q12hr on Day 1 then 500mg 
q24h
CVVH: 250mg q12h
CVVHD/CVVHDF: 500mg q8h
HD: 500mg q24h†
CVVH/CVVHD/CVVHDF: 1g q24h
HD: 15-20mg/kg q48h†
CVVH/CVVHD/CVVHDF: 15-20mg/kg q24h
HD: 200mg - 400mg q24h†
CVVH: 400mg q24h
CVVHD/CVVHDF: 400-800mg q24h
CrCl
30-50 ml/min
Unchanged
Unchanged
250mg q8h
1g q24h
Unchanged
CrCl
10-30 ml/min
400mg q24h - q12h
10mg/kg q48h
250mg q12hr
500mg q24h
15-20mg/kg q48h
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Refer Appendix C
Adjusted Maintenance Dose for Renal Impairment and Dialysis
Loading dose (LD) is required prior to Maintenance Dose (MD)
Drug / Normal Dose
Gentamicin
Imipenem
LD : 1g
MD : 1g q8h
Levofloxacin
LD : 750mg  
MD : 750mg q24h
Meropenem
LD : 1g - 2g
MD : 1g - 2g q8h 
*higher dose for CNS infection, 
MDR organisims
Oseltamivir
75mg q12h
CrCl
< 10 ml/min
500mg q12h
500mg q48h
500mg q12h - q24h
No data
Renal Replacement Therapy
HD: 500mg q12h†; CVVH: 500mg q8h
CVVHD/CVVHDF: 500mg q6h
HD: 500mg q48hr
CVVH: 250mg q24h
CVVHD: 500mg q24h
CVVHDF: 750mg q24h
HD: 0.5g - 1g q24h + 250-500mg AD
CVVH/CVVHD/ CVVHDF: 1g - 2g q12h
HD: 75mg q24h†
CVVH/CVVHD/ CVVHDF: 75mg q12h
CrCl
30-50 ml/min
500mg q6h
750mg q48h
1-2g 12h
75mg q24h
CrCl
10-30 ml/min
500mg q8h
500mg q48h
500mg - 1g q12h
75mg q24h
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Refer Appendix C
Adjusted Maintenance Dose for Renal Impairment and Dialysis
Loading dose (LD) is required prior to Maintenance Dose (MD)
Crcl < 50 ml/min use oral formulation as carrier vehicle of IV 
formulation accumulates.
BW > 40kg: 400mg q12h on Day 1, then 200mg q12h
BW < 40kg: 200mg q12h on Day 1, then 100 mg q12h
Drug / Normal Dose
Piperacillin/Tazobactam
LD : 4.5g
MD : 4.5g q6h
Pyrazinamide
20 -30mg/kg q24h
Streptomycin*
12 - 15mg/kg/dose q24h
(Max dose 1g)
*Dose range for Tuberculosis
Trimethoprim/Sulfamethoxazole
5mg/kg q8h - q6h*
(TMP component)
*Higher dose for PCP
Vancomycin
Voriconazole
Day1 : 6mg/kg q12h
MD : 4mg/kg q12h
CrCl
< 10 ml/min
2.25g q6h
12-15mg/kg q48h
5-10mg/kg q24h*
Renal Replacement Therapy
HD: 2.25g q6h†
CVVH: 2.25g q6h
CVVHD/CVVHDF:4.5g q8h
HD: 20 - 30mg/kg q48h†
HD/CVVH/CVVHD/CVVHDF:
12-15mg/kg q48h
HD: 5-10mg/kg q24h*†
CVVH/CVVHD: 5mg/kg q12h
CVVHDF: 10mg/kg q12h
HD/CVVH/CVVHD/CVVHDF: As per oral 
dosing in CrCl < 50ml/min
CrCl
30-50 ml/min
4.5g q6h
Unchanged
Unchanged
5mg/kg q8h
CrCl
10-30 ml/min
4.5g q8h
12-15mg/kg q48h
5mg/kg q12h
20-30mg/kg q48h
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HD: hemodialysis     CVVH: continuous venovenous hemofiltration     CVVHD: continuous venovenous hemodialysis
CVVHDF: continuous venovenous hemodiafiltration     AD: after dialysis     †Denotes drug that is dialysable however no clear 
recommendations for supplemental dosing. If HD is not significantly delayed, serve the dose after HD. If HD is significantly delayed 
consider serving dose as scheduled.
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Polymyxin E (Colistin)
Polymyxin is increasingly used as a last resort antibiotic to treat multi-drug resistant organisms like extreme-drug 
resistant Acinetobacter baumanii and carbapenem-resistant Enterobacteriaceae or Pseudomonas aeruginosa.
It is a hydrophilic drug that has concentration-dependent with time-dependent kill characteristics. 
Polymyxin E is available as Colistimethate Sodium (CMS) while its active drug is colistin. The following are some 
measures to optimise the use of polymyxin:
	 •	 Administer	a	loading	dose	as	CMS	conversion	to	Colistin	is	slow	and	incomplete.
	 •	 For	isolates	of	MIC	<	1mg/ml,	target	plasma	concentration	of	2mg/L	is	recommended.
	 •	 The	main	side	effects	are	nephrotoxicity	and	neurotoxicity.	The	risk	of	nephrotoxicity	must	be	balanced
  against the severity of infection and potential for treatment failure. Signs of neurotoxicity may not be 
  apparent in ventilated patients.
	 •	 Beware	of	underdosing	in	patients	with	augmented	renal	clearance	(CrCl	>	130ml/min/1.73m2 e.g. burns,
  sepsis, trauma).
	 •	 Combination	therapy	may	need	to	be	considered	on	case-to-case	basis	if	MIC	of	organism	is	>	1mg/L	in	
  patients.
	 •	 Colistin	is	efficiently	cleared	by	HD.	On	dialysis	day,	dialyse	towards	end	of	a	dosage	interval	and	administer	
	 	 a	supplemental	dose.	On	a	non-HD	day,	dose	as	for	creatinine	clearance	<	10ml/min.
	 •	 Colistin	 is	 also	 effectively	 cleared	 during	 CRRT	 hence	 the	 new	 higher	 dosing	 recommendations	 of	 4	
  million units q8h ( which averages about 0.5 million units/hour). This dose has been safely administered 
  during CRRT using AN69 ST (Surface Treated) membrane filters (which has high colistin adsorption) with 
  citrate anticoagulation. However use with other filters may shorten the filter life and lead to toxicity.
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Ideal Body Weight (kg)*
> 75
61-74
51-60
< 50
Creatinine Clearance (ml/min)
> 50
30-50
10-30
< 10
CVVH/CVVHDF
HD
SLED 4 hour
SLED 6 hour
Loading Dose
9 million units
8 million units
7 million units
6 milliion units
Maintenance Dose (MD) in million units (MU)
4.5 MU q12h
3 MU q12h
2.5 MU q12h
2 MU q12h
4 MU q8h*
*IMPORTANT: Cease this dosing regimen when CVVH 
stops to prevent toxicity
2MU q12h + 1.5 MU AD
2 MU q12h + 1.5 MU after SLED
2 MU q12h + 2.5 MU after SLED
Starting time of MD after LD (hours)
12
12
12
12
8
8
8
Loading Dose
Maintenance Dose
*Refer Appendix E for IBW calculation
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Sulbactam
In Ampicilin/Sulbactam (Unasyn), the ratio of ampicillin to sulbactam is 1:0.5
Sulbactam
Ampicillin/Sulbactam
(Unasyn)
Estimated creatinine clearance (ml/min) Renal Replacement Therapy
> 50
9g/day
9g q8h
20-50
6g/day
6g q8h
< 20
4g/day
6g q12h
HD
4g/day
6g q12h
CVVH/CVVHD/CVVHDF
9g/day
9g q8h
Bibliography:
1. Clin Infect Dis 2017 64 (5): 565-571
2. J Transl Intern Med 2013; 1: 6-8
3. Antimicrob Agents Chemother 2011; 55: 3284-94
4. Consensus Guidance on High Dose Colistimethate Sodium 
 (Colistin) in management of Carbapenemase producing 
 enterobacteriaceae (CPE) in Adults NHS Scotland, 2016 
5. Antimicrob Agents Chemother 2013; 57: 668-671
6. Clin Infect Dis 2016 Mar 1; 62(5): 552-558
7. J Infect. 2008; 56: 432-436
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APPENDIX B
DOSAGE ADJUSTMENT FOR HYPOALBUMINAEMIA
Recommendations for dosing highly protein-bound antibiotics in patients with hypoalbuminaemia ( serum albumin < 30g/L)
Antibiotic
Ertapenem
Ceftriaxone
Cloxacillin
Vancomycin
Standard ICU dosing
1g q24h
1g q12
2g q4h
1g q12h 
(15-20mg/kg q12h)
Recommended 
Loading Dose
2g
2g
2g
20-30mg/kg
Recommended Maintenance Dose
Increase frequency of administration:
1g q12h
Increase frequency of administration:
1g q8h
Consider continuous infusion:
12g q24h
Increase dosing: 1.5g q12h
Or	consider	continuous	infusion	(e.g.	3g	q24h)
Monitor trough concentrations to target concentrations > 15mg/L
Bibliography:
1. Clin Pharmacokinet 2011; 50(2): 99-110
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CrCl (ml/min)
> 60
40-60
20-40
< 20
HD
CVVH/CVVHD/CVVHDF
Dose and interval*
1mg/kg q8h or 3mg/kg q24h
1mg/kg q12h or 2 mg/kg q24h
1mg/kg q24h
1mg/kg q24h then redose when trough level < 1mg/L
1mg/kg q24h then redose when trough level < 1mg/L
Loading dose 3mg/kg followed by
1mg/kg q24h
GENTAMICIN IN ENDOCARDITIS
APPENDIX C
THERAPEUTIC DRUG DOSING AND MONITORING
*Use actual BW if malnourished and adjusted BW if > 20% ideal BW. In others, use ideal BW. Refer Appendix E for BW 
formulae.
Initial assay:
Repeat assay:
Sampling time:
Trough and peak with 3rd dose
Every 3-7 days or more frequent if changing renal profile
Trough: ½ hour before next dose
Peak: 30 mins after completion of 30 mins infusion
134
Target serum 
concentration 
(mg/ml):
Dose 
adjustment / 
Interpretation:
Exclusion
criteria:
Initial dose:
Initial assay:
Trough (< 1mg/L) and peak (10-12mg/L)
Consult pharmacist
- Age < 13 
- Burns > 20%
- Ascites
- Synergistic dosing for gram-positive infections (e.g. endocarditis) 
- History of ototoxicity
- Pregnancy
Gentamicin: 7mg/kg 
Amikacin: 15mg/kg
(Use actual BW if malnourished and adjusted BW if > 20% ideal BW. In others, use ideal BW. Refer 
Appendix E for BW formulae)
Single assay 6-14 hours after infusion of first dose.
Peak and trough serum levels are not routinely done.
Aminoglycoside (high dose extended interval dosing/single daily dosing)
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Repeat assay:
Dosing interval
following 1st
dose:
Once	weekly	or	more	frequent	in	patients	requiring	q36h	or	q48h	dosing,	changing	renal	function	or	on	
other nephrotoxic drugs.
For gentamicin, plot concentration on the Hartford nomogram below to determine the dosing interval. If the 
level:
- falls on a borderline, use the longer interval. 
- falls above the q48h dosing interval, reevaluate the need for continued therapy
- is < 2 μg/ml, and continue current regimen if the patient is clinically stable or improving. If not, re-evaluate 
  clinical situation (e.g. repeat level, change to traditional dosing, change antibiotics)
For amikacin, divide the measured concentration by 2 before plotting on the nomogram to determine the 
dosing interval.
Hartford Hospital High Dose Extended Interval Aminoglycoside Nomogram
Co
nc
en
tr
at
io
n 
(m
g/
L)
Time between start of infusion and sample draw (h)
6 7 8 9 10 11 12 13 14
14
13
12
11
10
9
8
7
6
5
4
3
2
Q48h
Q36h
Q24h
Applicable only to gentamicin dosing of 7mg/kg (or amikacin 15mg/kg)
Unit: mg/L = ug/ml
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15-20mg/kg/dose or 25-30mg/kg/dose in severely ill (Use actual BW. Refer Appendix E for BW formulae.)
(Not to exceed 2g per dose, infusion rate max 1g per hour to avoid Red Man Syndrome)
15-20mg/kg/dose (Use actual BW Refer Appendix E for BW formulae.)
CrCl (mL/min) Dosing Interval
> 50 q12h
30-50 q24h
< 30 Need longer intervals, determine by
 serum concentration monitoring
Haemodialysis Following loading dose of 15-20mg/kg, 
 given 500mg to 1000mg after each 
 dialysis session.
              CVVH 1g every 48 hours or 500mg every 24hours CVVHD/CVVHDF 1g every 24 hours
Normal renal function: After 3rd dose 
Impaired renal function: After 24 hours
Once	weekly	monitoring	in	hemodynamically	stable	patients.	More	frequent	or	daily	monitoring	in	patients	
who are hemodynamically unstable and changing renal function.
Loading Dose:
Maintenance 
dose:
Dosing interval
(Based on 
creatinine 
clearance):
Initial assay:
Repeat assay:
Vancomycin
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Trough:
Regular interval dosing: just before next dose 
Stat/Intermittent dosing: Random level: 12-36 hours after stat dose
Peak: not recommended due to extreme inter-patient variability and lack of correlation with either efficacy or 
toxicity
Trough: 10-15 μg/ml in conditions other than listed below
 15-20 μg/ml in bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia
If level is < 10μg/ml (or < 15μg/ml in target levels of 15-20μg/ml), decrease the dosing interval by one step, 
in steps of q12h, q24h, q36h, and q48h. If receiving the dose q12h, increase the dose by 250-500mg or 
consider q8h.
If the trough level is > 15μg/ml (or > 20μg/ml if target level is 15-20μg/ml), increase the dosing interval by 
one step.
Sampling time:
Target serum 
concentration:
Dose 
adjustment:
(Based 
on trough 
concentration)
Bibliography:
1. Therapeutic Guidelines: Antibiotic, Therapeutic Guidelines,
 Edition 14, Melbourne, Victoria 2010
2. Am J Health Syst Pharm; 2009; 66: 82-98
3. Bedside ICU Handbook: Tan Tock Seng Hospital, Singapore
138
The use of extended or continuous infusions of ß-lactam antibiotics has been shown to improve the time 
the free drug remains above MIC which predicts the killing characteristic of the antibiotic. This is pertinent 
when dealing with multi-drug resistant organisms. A loading dose must be given prior to regular dosing of the 
antimicrobial followed by either:
	 •	 Extended	infusion:	Infusion	lasting	3-4	hours,	usually	50%	of	dosing	interval.
	 •	 Continuous	infusion:	Infusion	over	24	hours	at	a	fixed	rate.
The diluted antibiotic should be stable throughout the infusion duration at room temperature of less than 24°C 
and has no incompatibilities with other medication administered concurrently. The stability may differ with 
different manufacturers.
APPENDIX D
EXTENDED OR CONTINUOUS INFUSIONS OF ß-LACTAMS
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Antibiotic
Ampicillin/
Sulbactam*
*For high dose 
sulbactam
Cefepime
Ceftazidime
Doripenem
Imipenem
Meropenem
Piperacillin/
Tazobactam
Loading dose 
over 30mins
2g
2g
500mg
1g q8h
1-2g
4.5gm
Duration of infusion
Extended over 4 hours
Extended over 4 hours 
Or
Continuous infusion over 
interval prescribed
Extended over 4 hours 
Or
Continuous infusion over 
interval prescribed 
Extended over 4 hours
Extended over 4 hours
Extended over 4 hours
Extended over 4 hours
Or
Continuous infusion over 
interval prescribed
Notes
3g of ampicillin/sulbactam dilute in 70mls of normal saline or 
dextrose 5%.
1 or 2g of cefepime in 50mls normal saline. 
1-2g dilute in 50mls normal saline.
500mg: dilute in 50mls normal saline.
500mg or 1g: dilute in 100-200mls normal saline (5mg/ml). 
500mg or 1g: dilute in 50mls normal saline. 
2g: dilute in 100mls normal saline.
2.25g or 4.5g: dilute in 50mls normal saline.
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Obese patients have a significant increase in fat mass as well as a smaller increase in lean tissue. This can make 
it difficult to determine a dosing weight for an obese patient. A number of different body weights (BW) are used 
for different purposes (actual, ideal and adjusted BW). Some antibiotics have sufficient data to be able to make 
recommendations, whereas others may need to use doses at the upper end of the recommended range or use 
modifications based on pharmacokinetic/pharmacodynamic principles. In obese patients:
	 •	 Oral	bioavailability	does	not	change.
	 •	 For	hydrophilic	drugs,	generally	no	change	in	volume	of	distribution	(Vd) since they have limited distribution 
	 	 in	body	fat,	hence	loading	dose	is	unaffected.	For	lipophilic	drugs,	there	are	large	increases	in	Vd and larger 
  loading doses are required. 
	 •	 The	renal	and	hepatic	clearance	of	many	drugs	is	increased.	However,	patients	with	severe	fatty	infiltration	
	 	 of	 liver	 have	 poor	 hepatic	 function	 and	 reduced	 drug	 clearance.	 For	 drugs	with	 increased	 clearance,	
  maintenance dose should be based on adjusted body weight.
	 •	 Creatinine	clearance	using	the	Cockcroft	and	Gault	formula	is	calculated	base	on	adjusted	body	weight.	
	 	 Alternative	 calculation	 for	 CrCl	 is	 the	 CKD-EPI	 (Chronic	 Kidney	 Disease	 Epidemiology	 Collaborative)	
  equation with the removal of body surface area nomalisation.
APPENDIX E
DRUG DOSING IN THE OBESE (BMI > 30kg/m2)
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Abbrev.
ABW
IBW
AdjBW
No
1
2
3
4
5
6
Definition
Actual body weight
Ideal body weight
Adjusted body weight
(Estimate	of	fat	free	
mass)
Drug
IV	Acyclovir
IV	Amikacin
IV	Amphotericin	B	
IV	Ampicillin
IV	Benzylpenicillin
IV	Cefazolin
IBW
√ 
√
ABW
√
√
√
AdjBW
How to estimate
Weigh patient
Male: 50 + [0.91 x (height{cm} 
-	152.4)
Female:	45.5	+	[0.91	x	(height{cm}	
-	152.4)
IBW	+[	0.4	x	(ABW	-	IBW)]
Application
Loading dose for lipophilic drugs.
Maintenance dose of drugs where clearance is unchanged 
in obesity
Maintenance dose of drugs with increased clearance in 
obesity
Remarks
BMI ≥ 40kg/m2:	use	AdjBW,	followed	by	TDM-based	dose	adjustment.
Consider	capping	at	2-2.5g	per	dose.
Both conventional & liposomal products.
Use upper end of recommended doses or use more frquently.
Use higher end of recommended dose.
(3-4MU	q4-6h)	in	severe	infections.	
Use a 2g per dose in adult obese patients.
Weight used for dosing
For	example	a	160kg	man	whose	height	is	170cm	(BMI	=	55.4).					ABW	=	160kg,	IBW	=	66kg	and	AdjBW	=	103.6kg
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No
7
8
9
10
11
12
13
14
15
Drug
IV	Ceftriaxone
IV	Ciprofloxacin
IV	Clindamycin
IV	Colistimethate
(Polymyxin	E)
IV	Daptomycin
Oral	Ethambutol
IV	Fluconazole
IV	Flucytosine
IV	Ganciclovir
IBW
√
√
ABW
√
√
√
AdjBW
√
√
Remarks
Use higher end of recommended dose.
Loading dose 2g followed by 2g q12h.
4-5mg/kg/dose.	
It is also suggested that 600mg q12h is better than 400mg q8h
Doses	of	800mg	q12h	in	morbid	obesity	have	been	used.
Serious	infection:	600mg	-	1.2g	in	divided	2-4	divided	doses.
In	 life	 threatening	 infections	 -	 use	 doses	 up	 to	 4.8g	 daily	 in	 divided	
doses (1200mg q6h).
Doses	 of	 <	 10mg/kg/24h	 have	 been	 shown	 to	worsen	 outcomes	 in	
morbidly obese.
Refer to appendix A.
Max daily dose 1.6g.
Based	on	higher	end	of	6-12mg/kg.
Weight used for dosing
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No
16
17
18
19
20
21
22
23
24
25
Drug
IV	Gentamicin	
Oral	Isoniazid
IV	Linezolid
IV	Metronidazole
IV	Meropenem
IV	Piperacillin/Tazobactam
Oral	Pyrazinamide
Oral Rifampicin
IV/IM	Streptomycin
IV	Trimethoprim	/	
Sulfamethoxazole
IBW
√
√
√
√
ABW
√
√
AdjBW
√
√
Remarks
AdjBW	used	for	initial	dose	followed	by	TDM-based	dose	adjustment.
Max daily dose 300mg.
Patients	weighing	≤ 150kg, use 600mg q12h.
Sufficient for treating skin & soft tissue infections.
Use	standard	dosing.	Doses	up	to	7.5mg/kg	(up	to	1g)	q6h	can	be	used	
for treatment of anaerobic bacterial infections.
Use standard dosing, however consider dosing of upper end of 
recommended dose e.g. 2g q8h.
Give	as	continuous	infusion	especially	for	isolates	with	high	MIC.
Max 2g/day.
Max daily dose 1.2g.
Max daily dose 1g.
Use AdjBW if > 20% ideal BW. In others, use ideal BW.
Weight used for dosing
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No
26
27
28
Drug
IV	Vancomycin
IV	Voriconazole
IV	Anidulafungin
IV	Doripenem
IV	Ertapenem
IBW ABW
√
AdjBW
√
Remarks
ABW	used	 for	 initial	 dose	 followed	 by	TDM-based	 dose	 adjustment.	
May need to shorten interval to maintain increased trough level of
15-20mg/L	e.g.	q8h.
Use IBW or Adj BW in morbidly obese.
Use standard dosing.
Weight used for dosing

